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THE ROLE OF MUCOSAL EPITHELIAL CELLS IN HIV-1 INFECTION
Publication No. __________
Danielle R. Fontenot, BS, MS
Supervisory Professor: K. Jagannadha Sastry, PhD
The predominant route of human immunodeficiency virus type 1 (HIV-1) transmission
is infection across the vaginal mucosa. Epithelial cells, which form the primary barrier of
protection against pathogens, are the first cell type at these mucosal tissues to encounter the
virus but their role in HIV infection has not been clearly elucidated. Although mucosal
epithelial cells express only low levels of the receptors required for successful HIV infection,
productive infection does occur at these sites. The present work provides evidence to show that
HIV exposure, without the need for productive infection, induces human cervical epithelial
cells to produce Thymic Stromal Lymphopoietin (TSLP), an IL7-like cytokine, which potently
activated human myeloid dendritic cells (mDC) to cause the homeostatic proliferation of
autologous CD4+ T cells that serve as targets for HIV infection. Rhesus macaques inoculated
with simian immunodeficiency virus (SIV) or with the simian-human immunodeficiency virus
(SHIV) by the vaginal, oral or rectal route exhibited dramatic increases in: TSLP expression,
DC and CD4+ T cell numbers, and viral replication, in the vaginal, oral, and rectal tissues,
respectively within the first 2 weeks after virus exposure. Evidence obtained showed that HIVmediated TSLP production by cervical cells is dependent upon the expression of the cell
surface salivary agglutinin (SAG) protein gp340. Epithelial cells expressing gp340 exhibited
HIV endocytosis and TSLP expression and genetic knockdown of gp340 or use of a gp340blocking antibody inhibited TSLP expression by HIV. On the other hand, gp340-null epithelial
cells failed to endocytose HIV and produce TSLP, but transfection of gp340 resulted in HIVinduced TSLP expression. Finally, HIV-induced TSLP expression was found to be mediated
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by TLR7/8 signaling and NF-kB activity because silencing these pathways or use of specific
inhibitors abrogated TSLP expression in gp340-postive but not in gp340-null epithelial cells.
Overall these studies identify TSLP as a key player in the acute phase of HIV-1
infection in permitting HIV to successfully maneuver the hostile vaginal mucosal
microenvironment by creating a conducive environment for sustaining the small amount of
virus that initially crosses the mucosal barrier allowing it to successfully cause infection and
spread
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CHAPTER 1
Introduction
Background on HIV Infection
The human immunodeficiency virus (HIV) is a double stranded RNA virus belonging to
the Lentivirus genus and the Retroviridae family [1-4]. The viral genome contains 2 identical
(+) RNA strands that are non-covalently bound and are approximately 9.5 kb in size [5]. Upon
entry of the target cell the single-stranded RNA is reverse transcribed by the viral RNAdependent DNA polymerase, also referred to as the reverse transcriptase [3, 5]. Two distinct
sub-types of HIV, HIV-1 and HIV-2, are identified based on their introduction into human
population as well as by their differential virulence to humans [1-4]. The HIV type 1, HIV-1, is
the descendent of chimpanzee derived simian immunodeficiency virus (SIVcpz), and it is the
more virulent of the two forms of HIV. HIV-1 accounts for the majority of human infections
worldwide [6]. The HIV type 2, HIV-2, is a descendent of SIV isolated from sooty mangabey
monkeys (SIVsmm), and is generally found in West Africa. In humans, HIV-2 is less virulent
and less transmissible as compared to HIV-1 [7] and also exhibits a longer clinical latency
period and a lower rate of morbidity of the resulting disease. Nevertheless, infection by either
HIV-1 or HIV-2 ultimately leads to the development of AIDS in humans.
The HIV-1 infection process begins with the binding of the viral envelope surface
protein, a 120 kd glycoprotein, to the CD4 receptor on the target cell [8](Fig. 1.1).
Subsequently, the gp120 protein on the virion undergoes a series of conformational changes
required for binding to a chemokine receptor, termed co-receptor, on the host cell [8].
Different strains of HIV-1 are classified based on their usage of the chemokine co-receptor: the
T-cell-tropic viruses use the CXCR4 chemokine receptor and are referred to as X4 viruses
while the macrophage-tropic viruses use the CCR5 chemokine receptor and are referred to as
1

R5 viruses [9-11]. Strains of HIV-1 that use both types of chemokine co-receptors are referred
to as dual-tropic viruses [8]. Even though infected individuals harbor a mixture of these
different types of viral strains, it is generally believed that HIV-1 transmission in humans is
initiated with the infection by the macrophage-tropic HIV-1 strains but during progressive
infection, the virus shifts towards T-cell tropism. This shift in viral tropism usually occurs late
in the course of disease and marks an accelerated phase in the clinical disease progression [12].
Once the gp120-CD4 complex is bound to the appropriate co-receptor, additional
conformational changes expose the transmembrane glycoprotein gp41 which gets inserted into
the membrane of the target cell for subsequent fusion of the viral and target cell membranes
(Fig. 1.1). One consequence of HIV infection is the decline in the numbers of memory subsets
of CD4+ T cells and when this decline reaches below a critical level, HIV infected individuals
develop susceptibility to opportunistic infections that eventually culminate into the acquired
immunodeficiency syndrome (AIDS). In 2007, there were an estimated 33.2 million cases of
HIV infection worldwide with oral and genital mucosal infections accounting for the majority
of all reported cases of HIV-1 infection and transmission [13].

2

Fig. 1.1: Cartoon representing the process of HIV-1 entry into human cells: The surface
envelope glycoprotein gp120 of the virus binds to the CD4 receptor on the host cell membrane
resulting in conformational changes in gp120 (a) that enable co-receptor binding (b) followed
by the exposure of the gp41 transmembrane glycoprotein (c) for fusion of the viral and host cell
membranes (d). Reprinted from Cell, Vol 85, Doranz, B. et al., A dual-tropic primary HIV-1
isolate that uses CXCR4 and the b-chemokine receptor CKR-5, CKR-3, and CKR2b as fusion
cofactors, Pages 1149-1158, with permission from Elsevier.
Source: Doranz et al. [8]
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Fig. 1.1:
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Animal model for genital HIV transmission:
The rhesus macaque (Macaca mulatta) model is widely used to extensively study HIV
transmission. This model uses either the simian immunodeficiency virus (SIV), a primate
lentivirus closely related to HIV, or a laboratory-created hybrid virus called simian-human
immunodeficiency virus (SHIV) consisting of genes that encode the HIV envelope and the SIV
core. Both of these viruses can be easily transmitted to macaques by vaginal inoculation and
cause AIDS-like illness characterized by severe loss of CD4+ T cells and opportunistic
infections. This model of SIV/SHIV infection of macaques is similar to that of HIV in humans
in that the target cells, physiology, and immunology of the genital tract are comparable. Using
this model, Miller et. al. [14] described the propagation and dissemination of SIV after vaginal
transmission (Fig. 1.2). This study showed that between days 1-4 post-infection only a few
infected cells could be found in the vaginal tissue, the original site of inoculation, as well as at
distant gut-associated lymphoid tissues (GALT). However, beyond day 4 post-infection, there
was a substantial increase in infected cells at the local vaginal tissue and a concurrent increase
over days 10-14 at the GALT. These observations correlate well with later reports describing
mucosal SIV infection in rhesus macaques and HIV infection in humans, both of which result
in rapid depletion of intestinal CD4+ T cells by day 14 post-exposure [15]. This extreme level
of depletion of CD4+ T cells occurs primarily in the mucosal tissues of the gastrointestinal (GI)
tract where more than 60% of T lymphocytes reside [15-19] . It is unclear how the virus
effectively manipulates the mucosal microenvironment during and soon after exposure such
that the initial founder population of infected cells in the vaginal mucosa not only survives but
also leads to the systemic spread of infection. The role of the mucosal microenvironment,
specifically the mucosal epithelium in sensing HIV infection, triggering immune activation,
and promoting HIV spread and amplification remains unknown. A better understanding of the
5

detailed steps during the mucosal infection process should provide a framework for
understanding the propagation, dissemination, and establishment of infection during the acute
stage of infection.

6

Fig. 1.2: Model of delayed systemic SIV replication. Study from Miller et al. showing that
between days 1-4 post-infection only a few infected cells could be found in the vaginal tissue,
the original site of inoculation, as well as at distant lymphoid tissues. However, beyond day 4
post-infection, there is a substantial increase in infected cells at the local vaginal tissue and a
concurrent increase over days 10-14 at the distant lymphoid tissues. Reprinted from the
Journal of Virology, Vol 79, Miller, C.J. et al., Propagation and Dissemination of Infection
after Vaginal Transmission of Simian Immunodeficiency Virus, Pages 9217-9227, with
permission from the American Society for Microbiology.
Source: Miller et al.[14]
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Fig. 1.2:
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HIV Transmission through Mucosal Tissues and the Mucosal Microenvironment
The majority of all new HIV transmissions occur in women through vaginal intercourse,
a route that carries the lowest HIV transmission probability rate suggesting that the genital
epithelium fails to serve as a major barrier against HIV entry [20]. For successful virus
transmission, HIV must be efficient in devising strategies to cross the mucosal barrier of the
genital tract to infect CD4+T cells. Since oral and genital mucosal epithelial cells express low
to negligible levels of the receptors for HIV, in particular CD4, it is suggested that the virus
utilizes unconventional mechanisms to cross the genital epithelial cell layers [20, 21]. Studies
in the rhesus macaque model with SIV suggested that the initial targets of infection may
include Langerhans Cells (LCs), subepithelial T-cells and dendritic cells (DCs) within the
genital mucosa [14, 20, 22-29]. In order for HIV to reach these targets during mucosal
transmission, it must successfully penetrate the epithelial barrier. There are several proposed
mechanisms for how HIV-1 may cross the mucosal epithelium (Fig. 1.3). The susceptibility of
epithelial cells to HIV infection is controversial with some studies reporting productive HIV
infection in epithelial cell lines of gut origin based on the expression of certain
glycosphingolipids such as galactosylceramide (GalCer) on the epithelial cells [30-34]. Other
studies have suggested that genital epithelial cells can bind, transport, harbor, and transmit
virus to additional targets, but cannot be productively infected [21, 34-36].

Yet another

proposed mechanism for HIV transmission across the mucosal epithelium is by transmigration
of the virus and infected cells through the mucosal epithelial cells. The infected cells can
include CD4+ T cells and monocytes found in semen [20, 37, 38]. Langerhans cells (LC)
constitute another vehicle by which virus may traverse the mucosal epithelium. Since LC
express CD4, CCR5, and CXCR4 and can be found within the genital tract it has been
suggested that LC at these mucosal sites can capture HIV and migrate to the draining lymph
9

nodes where the virus is transmitted to CD4+ T cells, the main targets of HIV replication and
dissemination[39-41].

Whether or not the LC can be infected after exposure to virus

inoculation is still controversial. Some studies of vaginal mucosal transmission of SIV in
rhesus macaques demonstrated that submucosal LCs rapidly became infected after virus
inoculation while other studies suggest that the CD4+ T cells are the cells infected and that they
are the major source of infectious virus during the acute stages of infection [29, 42]. Ex vivo
studies have demonstrated that LCs are not required for, but may aid in, viral transmission [20].
It is also possible that HIV can be transmitted across the mucosal epithelium through breaches
in the epithelial layer resulting from trauma associated with sexual intercourse or as a result of
co-infection with other sexually transmitted diseases that can weaken the mucosal barrier [4345]. These breaks in the epithelial barrier allow the virus access to susceptible targets of
infection in the underlying tissues but studies in the rhesus macaque model have revealed that
barrier disruption is not necessary for successful viral transmission [27]. Finally, it is also
proposed that HIV can be transmitted across the mucosal epithelium by transcytosis /
endocytosis through the mucosal epithelium involving interactions with epithelial cell surface
molecules such as heparin sulfate, enabling infection of the nearby DC and CD4+ T cells [3436]. This pathway was initially proposed after virus was observed being transported into
endosome like structures after coming into contact with the surface of epithelial cells [20]. Ex
vivo studies using the cervical explant model have also shown that HIV-1 virions can be found
in endocytic compartments as well as in the cytosol of epithelial cells [20].

However,

elimination of heparin sulfate did not abrogate viral transcytosis suggesting that other host cell
factors may also be involved in viral transcytosis in epithelial cells [46, 47]. Several recent
reports have demonstrated a specific interaction of HIV with epithelial cells through the
binding of the HIV surface envelope protein gp120 to the cell surface salivary agglutinin
10

(SAG) glycoprotein gp340, a member of the scavenger receptor cysteine-rich (SRCR)
superfamily of proteins and protein splice variant of the Deleted in Malignant Brain Tumors I
(DMBT1) that can be either secreted or membrane-bound [21, 48, 49].

11

Fig.1.3:
Depiction of Potential routes of HIV transmission across the mucosal epithelial layers: a)
direct infection of epithelial cells; b) transcytosis through epithelial cells; c) transmigration of
infected donor cells; d) uptake by migratory Langerhans cells; e) direct entry through breaches
in the epithelial layer.

Reprinted by permission from Macmillan Publishers Ltd: Nature

Reviews Microbiology 2003.
Source: Shattock & Moore 2003 [44]
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Fig.1.3:
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Mucosal Epithelial Cells and Receptors: DMBT1
Glycoprotein-340 (gp340) is expressed as a splice variant of the Deleted in Malignant
Brain Tumors I (DMBT1), which has been identified as a member of the scavenger receptor
cysteine-rich (SRCR) family of proteins. These proteins are known for their role as pattern
recognition receptors for interactions with specific pathogen motifs that drive signaling events
[21, 48-[50]. Differentially spliced variants of DMBT1 can encode both secreted as well as
membrane associated proteins [21, 48-[50]. Abundant expression has been found in tissues
such as the lung, trachea, salivary glands, stomach and small intestine while minor expression
has been found in the testis, mammary glands, uterus and brain [50]. The gp340 protein, a cell
membrane associated splice variant of DMBT1 has been found to be expressed at high levels in
the lung and upon recognition of specific pathogen motifs has been shown to stimulate the
migration of alveolar macrophages [50]. The gp340 protein, as the salivary agglutinin (SAG)
protein, is the secreted splice variant of DMBT1 found in saliva and was initially identified
based on its role in the clearance of bacterial pathogens including S. mutans [39, 50, 51]. SAG
was the first DMBT1 splice variant to be identified to play a role in HIV infection [50].
Compared to the vaginal route, HIV transmission within the oral cavity is of low frequency
despite the presence of similar cell types in both oral and vaginal tissues. Fractionation of
human saliva led to the identification of SAG as an inhibitor of HIV infection in the oral cavity
[50[48, 52]. It was shown that SAG interaction with HIV leads to viral agglutination [53].
Immunoprecipitation assays showed that SAG binds to gp120 in an area different from the CD4
binding site, and it was reported that pretreatment of HIV with soluble CD4 resulted in
enhanced SAG-gp120 binding [39, 53-55]. Further studies revealed that SAG interacts with
HIV within the base of the V3 loop, an area that is well conserved within the viral genome ([48,
49, 52] Fig. 1.4). While the role of SAG in HIV biology has been studied in great detail, the
14

role of epithelial cell surface gp340 in HIV transmission across genital mucosa has only
recently begun to be characterized. Stoddard et al reported that gp340 is expressed on human
vaginal and cervical tissues and that the cells expressing the cell surface associated form of
gp340 are capable of binding and facilitating HIV transmission [21]. Based on these reports
showing that HIV is capable of interacting with epithelial cells surface gp340, I conducted
experiments in this investigation to determine the potential consequences of viral transmission
through the mucosal epithelial cells in terms of signaling processes for the production of
soluble immune mediators that can influence viral survival and/or infection in situ.

15

Fig.1.4: Model depicting interaction of gp340 SRCR domain with HIV gp120: a) Model
of the quaternary complex between the HIV surface envelope protein gp120, human cell
surface receptor CD4, and the antibody AB17b, which binds to the conserved confirmation
dependent epitope of gp120 that is exposed after gp120 is bound to CD4 (referred to as CD4
induced epitope), and the SRCR domain on gp340 on epithelial cells. b) Space filling model of
interaction between gp120 and SRCR domain on gp340.
Source: Wu et al 2004 [49]
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Fig. 1.4:
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Immune Mediators Produced by Epithelial Cells: Thymic Stromal Lymphopoietin
(TSLP)
Epithelial cells in the skin and respiratory tract secrete thymic stromal lymphopoietin
(TSLP) in response to allergens and bacteria [56]. TSLP is an IL-7 like cytokine that was
originally identified in the supernatants of the mouse thymic stromal cell line, Z210R.1 and was
reported to display a remarkable ability to support the long-term growth of a pre-B cell line as
well as promote proliferation of thymocytes [57-61]. Isolation of a cDNA clone encoding
human TSLP revealed that it is structurally similar to murine TSLP but shares only 43% amino
acid homology [59, 62, 63]. The TSLP receptor complex is a heterodimer consisting of a TSLP
receptor (TSLPR) binding chain and the interleukin 7 receptor-α (IL-7Rα) chain, which
together bind TSLP with a high affinity resulting in Signal Transducers and Activator of
Transcription-5 (STAT-5) activation and cell proliferation [58, 59]. Early studies demonstrated
that unlike murine TSLP, the human TSLP does not promote the differentiation and growth of
B cells nor does it have a direct effect to support the activation of T cells [59].
In humans, TSLP is mainly expressed by skin keratinocytes, epithelial cells, smooth
muscle cells, lung fibroblasts, or IgE stimulated mast cells. Microbial infection or allergen
exposure triggers mucosal epithelial cells to produce TSLP [56, 58] (Fig.1.5). TSLP upregulates activation markers such as CD54, CD80, CD83, CD86, DC-SIGN, and HLA-DR on
myeloid dendritic cells (mDC) and activates immature DC to produce the neutrophil and
eosinophil attractant chemokines Interleukin-8 (IL-8) and eotaxin-2 as well as the T helper 2
(Th2) attractant chemokines thymus and activation regulated chemokine (TARC or CCL17)
and macrophage-derived chemokine (MDC or CCL22) [58, 59, 64]. Unlike the DC activated
by a variety of factors, such as CD40-L, LPS and poly I:C , TSLP-activated DC do not produce
IL-12 the pro-inflammatory cytokines TNF, IL-1β, and IL-6, or induce TH1 responses [59,
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64]. Instead, mature TSLP-activated DC migrate to the draining lymph node, express high
levels of OX40L, trigger homeostatic proliferation of naïve CD4+ T cells and induce their
differentiation into a unique type of inflammatory Th2 cells that produce Interleukin-4 (IL-4),
Interleukin-5 (IL-5), Interleukin-13 (IL-13), and Tumor Necrosis Factor (TNF) and not the
classic Th2 cells that produce Interleukin-10 (IL-10) [58, 65]. These inflammatory Th2 cells
then migrate back to the site of inflammation due to the local production of TARC and MDC
by the TSLP-activated DC. These studies suggest that TSLP produced by epithelial cells plays
an important role in inducing allergic inflammatory responses [59].

This hypothesis is

supported by studies showing that the airway epithelium of asthma patients expresses increased
levels of TSLP and also that infection by rhinoviruses or exposure to pro-inflammatory
mediators such as IL-1β, TNF-α and some TLR agonists induce TSLP production in human
airway epithelial cells causing the exacerbation of asthma [66, 67]. Furthermore, TSLP is
highly expressed in patients with acute and chronic atopic dermatitis lesions and this increased
TSLP expression is associated with Langerhan cell migration and activation suggesting that
TSLP is a critical link between epithelial cells and the DC of the immune system at a molecular
level [64, 68]. The fact that TSLP produced by epithelial cells exposed to allergens and
microbes induces DC-mediated expansion of CD4+ T cells formed the basis for the central
hypothesis of this dissertation research that: HIV exposure at the mucosal tissues stimulates
epithelial cells to produce TSLP for DC-mediated expansion of susceptible target CD4 T
cells.
In 2007, Lee and Ziegler identified an NFκB site within the human TSLP gene
promoter that was critical for IL-1β and TNF-α induced TSLP expression [69]. This provided a
link for the mechanism by which TSLP expression is induced by ligands for TLR2, TLR8, and
TLR9. Since NFκB has such a broad range of activation signals, several labs explored the
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potential involvement of other factors for regulating TSLP expression. Li et al. identified two
nuclear receptor binding sites in both the human and mouse TSLP gene promoters, in particular
the retinoid X receptors (RXR) α and β for which 9-cis- retinoic acid (9-cis-RA) serves as a
high-affinity ligand [70]. Studies showed that keratinocytes with selective ablation of RXRα
and RXRβ display an inflammatory response similar to that of atopic dermatitis in humans
[70]. High levels of TSLP expression were also found in these cells. In 2008, Lee et al.
demonstrated that 9-cis-RA represses IL-1β mediated TSLP gene expression through direct
inhibition of NFκB binding and signaling [71]. These studies suggested that RXRα and RXRβ,
when bound to ligand, are involved in regulating TSLP expression and therefore, could
potentially be exploited for developing novel therapeutic strategies for asthma and atopic
dermatitis. Results from the current investigation point to similar application of the RXR
ligands for inhibiting HIV-induced TSLP expression by genital mucosal epithelial cells as a
strategy in the fight against the transmission of HIV.
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Fig.1.5: Pathology of TSLP-mediated inflammation
Microbial infection or allergen exposure triggers mucosal epithelial cells to produce TSLP.
TSLP activates immature DC to produce the neutrophil and eosinophil attractant chemokines,
interleukin-8 (IL-8) and eotaxin-2 as well as the T helper 2 (Th2) attractant chemokines,
thymus and activation regulated chemokine (TARC or CCL17) and macrophage-derived
chemokine (MDC or CCL22). Mature TSLP-activated DC migrate to the draining lymph node,
express high levels of OX40L, and trigger homeostatic proliferation and differentiation of naïve
CD4+ T cells into inflammatory Th2 cells that produce Interleukin-4 (IL-4), Interleukin-5 (IL5), Interleukin-13 (IL-13), and Tumor Necrosis Factor (TNF). These inflammatory Th2 cells
then migrate back to the site of inflammation due to the local production of TARC and MDC.
Source: Y.J. Liu, 2006 [58] (© Y.J. Liu, 2006. JEM, 203: 269-273)
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Fig.1.5:
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CHAPTER 2
Statement of Objectives
Genital mucosal infections account for the majority of the reported cases of human
immunodeficiency virus (HIV) transmission worldwide. Ironically, mucosal epithelial cells are
resistant to HIV infection because they express low to negligible levels of the receptors
necessary for productive HIV infection and also because the mucosal tissue microenvironment
is laden with numerous soluble antiviral factors and exhibits low pH. For these reasons, the
outcome of HIV exposure is dependent on the extent to which the virus can manipulate the
mucosal tissue microenvironment, specifically the epithelial cells. In this regard, it is known
that airway epithelial cells respond to exposure to allergens and bacteria by producing thymic
stromal lymphopoietin (TSLP), an IL7-like cytokine that can mediate allergic and
inflammatory T cell responses by acting directly on dendritic cells (DC) resulting in
homeostatic proliferation of T cells. Since T cells are the major targets for HIV infection and
their accessibility at the site of virus exposure could positively influence the successful
invasion by HIV, I hypothesized that HIV exposure at the mucosal tissues stimulates
epithelial cells to produce TSLP for DC-mediated expansion of susceptible target CD4 T
cells.

I obtained evidence to show that HIV exposure, without the need for productive

infection, induced human cervical epithelial cells to produce TSLP, which potently activated
human myeloid DC (mDC) to cause the homeostatic expansion of autologous CD4+ T cells that
served as targets for HIV infection.

The following three specific aims describe the

comprehensive approach and experimental design I adopted to test the hypothesis and
understand the potential role of epithelial cells for ensuing mucosal HIV infection through
TSLP production.
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Specific Aims:
1. Determine whether HIV-induces TSLP expression in epithelial cells. Various human
epithelial cell lines and primary keratinocytes were cultured with different laboratory adapted
as well as patient derived (primary) strains of HIV-1 and TSLP expression was monitored at
the RNA level by quantitative real time RT-PCR and at the protein level by ELISA and western
blot analyses. In order to determine the in vivo relevance, tissues or biopsies collected from
vaginal, oral, and the rectal mucosa of monkeys prior to and after infection with SIV or SHIV
by the respective route were analyzed for changes in TSLP expression by employing
immunohistochemistry and mRNA analyses. Collaborative studies using the human cervical
explant model further confirmed HIV-induced TSLP expression in the epithelial cells.
2. Determine the potential impact of HIV-induced TSLP expression by epithelial cells on
HIV infection of CD4 T cells. Since TSLP activated DC can promote expansion of CD4+ T
cells, purified DC from normal human PBMC were cultured with supernatants collected from
HIV exposed epithelial cells and analyzed for the expression of DC activation markers and for
the expression of the TH2 attractant chemokines CCL17 and CCL22. Subsequently, DC
treated with supernatants collected from HIV exposed epithelial cells were co-cultured with
purified autologous naïve CD4+ T-cells and T cell expansion was determined. The phenotype
of the resulting expanded cultures of T cells was determined in terms of cytokine mRNA
analyses by RT-RCR. The susceptibility of these CD4+ T cells resulting from co-culturing
with the TSLP-activated DC to HIV infection was assessed by RNA analyses for monitoring
the expression of the different HIV receptors. The degree of HIV infection of these CD4+ T
cells resulting from co-culture with TSLP-activated DC was measured by determining reverse
transcriptase activity in the culture supernatants. Biopsies collected from both vaginal and
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rectal tissues of monkeys infected with SIV or SHIV were tested for the correlation of
increased TSLP expression with increased viral infection in vivo.
3. Investigate the mechanism of HIV-mediated induction of TSLP expression in epithelial
cells. Epithelial cells have been shown to not express the typical receptors required for HIV
infection. One potential possibility for specific interaction of HIV with epithelial cells is
through the reported binding of the HIV envelope protein gp120 to the epithelial cell surface
salivary agglutinin (SAG) protein gp340 which has been proposed to be involved in HIV
transcytosis/endocytosis. I conducted experiments to test the hypothesis that HIV binding
to the epithelial cell receptor gp340 induces TSLP expression. Different epithelial cells
were screened for the expression of gp340 both by flow cytometry for cell surface expression
and by analyzing gp340 RNA expression.

A series of experiments were conducted to

determine the importance of gp340 for HIV-induced TSLP expression: by incubating gp340+
epithelial cells with HIV-1 in the presence or absence of a specific gp340 antibody; silencing
gp340 expression in gp340+ epithelial cells; and introducing gp340 into a gp340-null epithelial
cell line. HIV binding to gp340 alone was observed to be not sufficient for inducing the signals
needed for TSLP expression in experiments involving cross linking of immobilized HIV to
gp340+ C33A cervical epithelial cells. The potential role for gp340-mediated endocytosis of
HIV in inducing TSLP expression was tested by exposing epithelial cells to HIV in the
presence of a variety of inhibitors of endocytosis and measuring TSLP expression.

The

downstream TLR7/8-mediated signaling pathway of endocytosed HIV for inducing TSLP
expression was also investigated.

25

CHAPTER 3
Genital epithelial cells produce TSLP in response to immunodeficiency virus and trigger
dendritic cell-mediated expansion and infection of CD4+ T cells

Rationale: Genital mucosal epithelial cells express low to negligible levels of the receptors for
HIV and the genital mucosal microenvironment exhibits low pH and contains numerous
antiviral compounds. Thus, a major portion of the viral inoculum deposited at these locations
has little chance to survive and cause infection.

Yet, genital transmission, specifically

intravaginal exposure, accounts for majority of HIV infections acquired by women worldwide
[13, 72-75]. Therefore, it is important to understand the changes within the genital mucosal
microenvironment subsequent to viral exposure that enable the limited infectious virus and/or
the small founder population of infected cells within the genital mucosa to prevail and
successfully invade local as well as systemic tissues. Thymic stromal lymphopoietin (TSLP) is
an epithelial cell derived interleukin 7 (IL-7) like cytokine expressed in response to microbial
infection or allergen exposure [58, 76]. It has been shown that dendritic cells (DC) as well as
the Langerhan’s cell (LC), which reside within the genital mucosal tissues, are activated by
TSLP and exhibit unique phenotypic and functional characteristics, specifically the capacity to
induce homeostatic expansion of naïve CD4+ T cells [58, 76, 77].
Hypothesis: In this investigation, I tested the hypothesis that HIV entry at the mucosal tissues
stimulates epithelial cells to produce TSLP, which may activate DC leading to recruitment and
expansion of CD4+ T-cells, the ideal targets for enhanced HIV infection.
Experimental Design: To test the hypothesis, the following series of experiments were
conducted:
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•

A number of human epithelial cell lines and primary human keratinocytes were exposed
in vitro to a variety of HIV-1 strains to determine TSLP expression and production.

•

In rhesus macaques, the well-established nonhuman primate model for HIV infection,
the in vivo TSLP expression was determined in the vaginal, rectal and oral mucosa after
exposure

to

simian

immunodeficiency

virus

(SIV)

or

the

simian

human

immunodeficiency virus (SHIV), by the respective route.
•

TSLP expression in vaginal tissue explants was investigated after ex vivo exposure to
HIV.

•

Analyzed the effects of TSLP produced by HIV-exposed epithelial cells for activating
DC that in turn were tested for promoting the expansion of naïve autologus CD4+ T
cells and subsequent HIV infection.

•

Determined the phenotype and functional properties of CD4+ T cells resulting from coculturing with DC activated by TSLP from HIV-exposed epithelial cells.

•

Investigated the mechanism of HIV-mediated induction of TSLP expression in
epithelial cells and determined the potential role of the epithelial cells surface molecules
such as the gp340 scavenger receptor for interaction with HIV as well as the signaling
molecules for TSLP expression within the epithelial cells.
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Specific Aim 1: Determine whether HIV-induces TSLP expression in epithelial cells

Results
HIV induces production of TSLP in human epithelial cell lines and primary human
keratinocytes in vitro
To investigate whether HIV induces TSLP production in epithelial cells, human cervical
epithelial cells (C33A) were cultured with HIV-1 for 12-18 h at 37ºC and the cell extracts as
well as the culture supernatants were analyzed for TSLP expression. When compared with the
medium control treatment, HIV-1IIIB, in a concentration dependent manner induced an increase
in the levels of TSLP expression (Fig. 3.1a). Capacity to enhance expression of TSLP was not
restricted to the laboratory-adopted and T-cell tropic virus HIV-1IIIB, since exposure of the
epithelial cells to the macrophage tropic virus HIV-1YU2 as well as a primary HIV-1 isolate
93ZR001.3 resulted in increased TSLP RNA expression (Fig. 3.1b). Analysis of cDNA by RTPCR confirmed enhanced TSLP expression in these cells (Fig. 3.1c). Furthermore, culture
supernatants as well as cell lysates from the epithelial cells exposed to HIV-1IIIB showed
increased levels of TSLP protein as determined by ELISA and western blot analyses (Fig. 3.1df). Secreted TSLP protein could only be detected in the cell supernatants of 3 x106 cells or
above (Fig. 3.1d). As described in the literature, TSLP expression at the RNA and protein
levels was also observed with poly I:C but not lipopolysaccharide (LPS), which served as
positive and negative controls, respectively in these experiments [66]. HIV-induced TSLP
expression was also observed in several different human epithelial cell lines including human
neuroblastoma cells (SKNM), intestinal epithelial cells (HT29), and primary human
keratinocytes exposed to HIV-1IIIB, as well as in macaque epithelial cells (4MBr-5) incubated
with SHIV89.6P (Fig. 3.1F). However, TSLP expression was not observed in other cell types
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such as the fibroblast-like human osteosarcoma (GHOST X4) or lymphocytes such as the
human T-lymphoblastoid cells (H9 cells) exposed to HIV-1IIIB (Fig. 3.2).
It is known that epithelial cells corresponding to various anatomical locations in general
do not permit productive infection by HIV, even though infection and/or transcytosis of HIV
through certain epithelial cells is documented [34-36].

To test whether productive HIV

infection is required for the observed TSLP expression in epithelial cells, C33A cells were
cultured with HIV-1 that is pseudotyped with Vesicular stomatitis virus (VSV) envelope (VSVHIV) or inactivated by treatment with aldrithiol-2 (AT-2), a reagent shown to covalently
modify the essential zinc fingers in the nucleocapsid (NC) protein of HIV-1 thereby arresting
the viral life cycle before initiation of reverse transcription [78, 79]. As shown in Fig. 3.3, both
infectious as well as AT-2 inactivated X4 and R5 strains of HIV-1 (HIV-1MN and HIV-1ADA,
respectively), but not VSV-HIV, induced significantly increased levels of TSLP mRNA in the
epithelial cells. These results demonstrate that diverse HIV-1 strains, both infectious and
noninfectious, can efficiently induce TSLP expression in a variety of epithelial cells including
primary human keratinocytes.
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Fig. 3.1: HIV induces TSLP expression in cervical epithelial cells. Increased levels of
TSLP expression were dependent on the amount of HIV used to culture the C33A cervical
epithelial cells (a). Increased levels of TSLP mRNA were detected in cervical epithelial cells
(C33A cells exposed to HIV-1IIIB, HIV-1YU2, the primary clade D HIV isolate 93ZR001.3, or
polyI:C (5 ug/ml) when compared to medium alone or in cells cultured with LPS (10 ug/ml), as
assessed by quantitative real time PCR (b) and RT PCR (c). Increased levels of TSLP protein
were detected in the supernatants as well as the lysates of the C33A cells exposed to HIV-1IIIB,
HIV-1YU2 or polyI:C by ELISA (d and e) and also by western blot analysis (f). Data represents
average values along with standard deviation from three independent experiments.

Fold

increase in TSLP mRNA expression was shown for various HIV strains and poly I:C as
compared to medium control treatment.
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Figure 3.1:
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Fig.3.2:

HIV induces TSLP expression in a variety of epithelial cells but not non-

epithelial cells. As determined by quantitative real time PCR, increased levels of TSLP
mRNA were detected in neuronal (SKMN) and intestinal (HT29) epithelial cells, primary
human keratinocytes (Normal Human Epidermal Keratinocytes, NHEK), and monkey epithelial
cells exposed to immunodeficiency viruses but not in non-epithelial cells (human osteosarcoma
or T lymphoblastoid cells). Data represents average values along with standard deviation from
three independent experiments. Fold increase in TSLP mRNA expression was shown for
various HIV strains and poly I:C as compared to medium control treatment.
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Figure 3.2:
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H9 Ghost X4

Fig.3.3: Productive HIV infection is not necessary for TSLP induction. Increased levels of
TSLP mRNA were detected in C33A cervical epithelial cells cultured with infectious as well
as AT-2 treated non-infectious HIV-1ADA and HIV-1MN strains but not in medium alone or cells
cultured with VSV pseudotyped HIV. Data represents average values along with standard
deviation from three independent experiments. Fold increase in TSLP mRNA expression was
shown for various HIV strains and poly I:C as compared to medium control treatment.
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VSV-HIV

TSLP is expressed in vivo within the mucosal tissues of rhesus macaques infected with
simian immunodeficiency virus
To investigate whether the HIV-induced TSLP expression observed in the in vitro
studies with human epithelial cells also occurs after in vivo infection within the mucosal sites
of viral entry in the nonhuman primate model, vaginal tissues from rhesus macaques
intravaginally inoculated with the simian immunodeficiency virus, SIVmac251, were analyzed.
For this, we used rhesus monkey vaginal tissue samples available from an earlier study by our
collaborators from the California Primate Center, Davis, CA, where the animals were infected
by the vaginal route with SIVmac251 and vaginal samples were obtained after necropsy at
different time-points post-challenge [14].

Relative to before SIV infection (Fig. 3.4a),

immunohistochemistry analyses demonstrated high levels of TSLP in the vaginal mucosa
starting as early as day 1 post-inoculation (post-SIV) and was significantly higher by day 14
(Fig. 3.4b and c). The levels of TSLP expression correlated with a 41 and 99-fold increase in
TSLP expression at days 1 and 14 respectively, as determined by quantitative real time PCR
analyses of the mRNA isolated from the tissue samples (Table 1). This increase in TSLP
expression coincided with an increase in viral RNA positive cells between days 1 and 14 in
these tissues as determined by in situ hybridization (ISH) analyses at our collaborators’
laboratory in Davis, CA (Fig. 3.4d-f). Thus, there was a rapid and sustained increase in TSLP
expression in the vaginal mucosa of rhesus macaques after SIV inoculation. Similarly, mRNA
analyses of tonsil and rectal biopsies collected from rhesus macaques (at the UTMD Anderson
Cancer Center primate facility in Bastrop, TX) after atraumatic application of the chimeric
simian human immunodeficiency virus (SHIV) by the oral and rectal routes, respectively,
showed increased TSLP levels between days 4 and 7 post-infection (Figs. 3.5 and 3.6).
Concurrent with the increased TSLP expression in the tonsil tissues, we observed increased
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levels of thymus and activation regulated chemokine (TARC also known as CCL17), a TH2
cell attracting chemokine known to be expressed in TSLP-activated DC (Fig. 3.5b) [76, 80].
Coinciding with the increased TSLP expression in the rectal tissues, there was also an increase
in plasma viral RNA levels (Fig. 3.6). Furthermore, vaginal tissues with the high levels of
TSLP expression on day 1 post-infection exhibited significantly increased numbers of CD11C+
mDC and CD4+ T cells when compared to that from the vaginal tissues of an uninfected animal
(Fig. 3.4h and g; and Fig. 3.4j and i, respectively). These results support our in vitro data and
show that during the early stages of infection the mucosal microenviroment favors virus
expansion by recruiting large numbers of CD4+ T cell targets through DC that are activated in
response to TSLP from HIV-exposed epithelial cells.
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Fig. 3.4: Increased expression of TSLP along with higher numbers of CD11c+ mDC and
CD4+ T cells in vaginal mucosal tissues from rhesus macaques after vaginal SIV infection.
Samples collected from the vaginal tissues of rhesus macaques prior to (a, uninfected) and days
1 (b) and 14 (c) post-infection with SIVmac251 were used for immunohistochemial staining for
TSLP showed low levels of TSLP in the normal vaginal tissues, but higher levels after 1 and 14
days post-SIV exposure (red staining indicates TSLP protein expression). The sequential
samples were also subjected to in situ hybridization (ISH) analyses using radiolabeled
riboprobes. A low number of SIV RNA+ cells were observed at day 1 which increased
substantially at day 14 post-infection (shown with black arrows in panels e and f), relative to
tissue from an uninfected monkey (d).

Double staining for TSLP (purple) and CD11c+

dendritic cells (brown) showed higher numbers of mDC in the vicinity of TSLP staining in the
vaginal epithelium at one day after vaginal SIV infection (h) compared to that in uninfected
sample (g). Increased numbers of CD4+ cells (brown) were also observed in the vaginal tissue
at one day after SIV infection (i) compared to that from an uninfected animal (h).
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Table 1: SIV and TSLP RNA levels in the vaginal tissues of rhesus macaques prior to and at sequential time points after vaginal infection
with SIVmac251

Days post infection

vRNA* (copies/ug tissue RNA)

mRNA expression

0

-

1

3.6x104a

9

Quantification of IH staininge

Fold increase in TSLP

TSLP

CD11c

CD4

+

+

+

41

++

++

++

6.1x105b

425

++

10

5.1x105c

719

++

14

5.6x105d

99

++

++

++
++

+

++

* The vRNA data was previously published (19)
a

vRNA level is representative of one monkey from a group of 6 necropsied 1 day post infection. vRNA levels range from 4x102 to 3.6x104

b

vRNA level is representative of one of two samples taken from animal 28103 at 9 days p.i. vRNA levels were determined to be 6.0x105 by
repeat analysis.
c

vRNA level is representative of one of two samples taken from animal 24818 at 10 days p.i. vRNA levels were determined to be 5.0x105
by repeat analysis.

d

vRNA level is representative of one of two samples taken from animal 24037 at 14 days p.i. vRNA levels were determined to be 5.6x105
by repeat analysis.

e

Quantification of IH staining is based on visual observation
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Fig. 3.5: Expression of TSLP in the oral mucosal tissues collected from SHIV infected
rhesus macaques. (a) Increased levels of TSLP mRNA in SHIV infected tissues showing the
highest levels on days 4 and 7 in the palatine tonsils and pharyngeal tonsils. (b, c) Increased
levels of TARC and CD4 mRNA were also detected in the SHIV infected tissues collected with
the highest levels detected on days 4 and 7 in the palatine and pharyngeal tonsil tissues
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Fig. 3.6: Expression of TSLP in the rectal mucosal tissues collected from SHIV infected
rhesus macaques. Increased levels of TSLP mRNA were detected after rectal inoculation with
SHIV162P3 within the rectal tissue biopsies collected at different time points post-infection from
animals Rh 57 (a), Rh 65 (b), and Rh H196 (c). Increased TSLP levels coincided with increased
plasma viremia levels shown on the Y-2 axis in each panel.
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TSLP is expressed in the vaginal mucosal tissue explants infected with human
immunodeficiency virus ex vivo
Because in vitro models are based on cells lines which do not provide the natural cellular
structures of female genital mucosal tissues that may be important in viral transmission, we
examined the HIV-induced TSLP expression in a cervical explant model in collaboration with
our colleagues from the Fred Hutchinson Cancer Center, Seattle, WA [29]. This model uses
vaginal tissues rather than cell lines which provides the natural structure, including epithelial
cells, dendritic cells (Langerhan’s cells, LC) and T cells to allow observation of how HIV targets
cells of the vaginal mucosal tissue [29]. The squamous vaginal epithelium, the initial barrier to
infection, is separated from the underlying stroma and the tissues are exposed to HIV. Within
four hours of HIV exposure, TSLP expression could be detected by mRNA analysis in the
epithelial sheet and the explant tissues which continued to significantly increase up to 4 days
post exposure (Fig. 3.7). This was further confirmed by confocal microscopy. Relative to before
HIV infection (Fig. 3.8a), confocal microscopy demonstrated high levels of TSLP in the vaginal
mucosa (green color staining) starting as early as day 1 post-infection that significantly increased
by day 5(Fig. 3.8b and c). TSLP expression, assessed by real-time RT-PCR analyses, was only
detected in the epithelial sheet and explant tissues and not the separated underlying stroma
further confirming the mucosal epithelial cells as the source of TSLP production (Fig. 3.7).
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Fig. 3.7: Expression of TSLP by epithelial cells in cervical explant tissues.
Samples collected from human cervical explant tissues exposed to HIV at different time points
used for mRNA analysis of TSLP expression showed an increase in TSLP production over time
in the epithelial sheet and whole cervical explant tissue, but not the separated underlying stroma
tissue. The fold increase shown was calculated using the control tissue from each time point as
the background value for comparing TSLP expression in the infected tissues.
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Figure 3.7:
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Fig. 3.8:

Increased expression of TSLP in human cervical explant tissues after HIV

infection. Samples collected from human cervical explant tissues exposed to 100ng/ml HIV at
different time points were used for confocal analysis of TSLP expression. Tissues showed an
increase in TSLP production over time. The TSLP levels are higher on day 5 compared to day
1. Green color represents TSLP staining, red represents Langerhans cells, and blue represents
nuclei.
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Specific Aim 2: Determine the potential impact of HIV-induced TSLP expression by
epithelial cells on HIV infection of CD4 T cells

Results
TSLP from HIV exposed epithelial cells activates human CD11c+ myeloid dendritic cells
Human myeloid DC (mDC) exposed to TSLP exhibit up-regulation of the activation
markers CD40, CD80 and CD86, along with induction of the production of the chemokines
CCL17 and CCL22 [76, 80]. To determine the biological activity of TSLP produced in the
supernatants of HIV exposed epithelial cells, highly purified CD11c+ mDC isolated from human
peripheral blood mononuclear cells (PBMC) by fluorescence activated cell sorting were
incubated with supernatants of epithelial cells cultured with HIV (HIV+Sn), recombinant TSLP
(rTSLP) at 100ng/ml, or culture medium (medium) for 24h and the expression of activation
markers on DC and production of chemokines were assessed (Fig. 3.9). In a manner similar to
rTSLP, HIV+Sn dramatically up-regulated CD80, CD86, and CD40 expression on mDC after 24
hours of culture (Fig. 3.9). The ability of HIV+Sn and rTSLP to up-regulate CD40, CD80 and
CD86 expression could be abrogated by neutralizing TSLP antibodies (Fig. 3.9). Both rTSLP
and HIV+Sn stimulated mDC to produce high levels of thymus and activation regulated
chemokine (TARC or CCL17) and macrophage-derived chemokine (MDC or CCL22) at both the
mRNA and protein levels (Fig. 3.10). The activity of TSLP within the HIV+Sn, along with that
of rTSLP for inducing chemokine production could also be blocked by neutralizing TSLP
antibodies (Fig. 3.10).
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Fig. 3.9:

TSLP within the supernatant from HIV exposed epithelial cells potently

activates human CD11c+DCs. Supernatant from HIV exposed C33A cells (HIV+Sn) and
recombinant TSLP (rTSLP) potently activate mDC in terms of up-regulation of CD40, CD80
and CD86 expression on CD11c+DC as compared to cells cultured with medium. The ability
of HIV+Sn and rTSLP to up-regulate CD80 and CD86 expression could be abrogated by
neutralizing TSLP antibodies. The open histograms represent the isotype control and the filled
histograms represent staining of DC activation markers. Numbers in each panel indicate the
mean fluorescence intensity (MFI) values.
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Figure 3.9:
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Fig. 3.10:

TSLP within the supernatant from HIV exposed epithelial cells induces

expression of chemokines by DC. DCs stimulated with supernatant collected from HIV
exposed C33A cells (HIV+Sn) and recombinant TSLP (rTSLP) produced high levels of the
chemokines CCL17 and CCL20 as determined by mRNA (upper panels) and protein analysis
(lower panels). Production of the chemokines was blocked in mDC that were pretreated with a
TSLP-specific antibody (α-TSLP). Data represents values from one of three independent
experiments.
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Myeloid DC activated by TSLP from HIV exposed epithelial cells induce CD4+ T cell
expansion and HIV infection in vitro
To further delineate the biological activity of the HIV-induced TSLP, mDC activated by
the culture supernatants of HIV-exposed epithelial cells (HIV+Sn/DC) were co-cultured at a 1:
1 ratio with autologous, naïve CD4+ T cells for 7 days. Since HIV preferentially infects the
memory subset of CD4+ T cells and because these cells are lost earlier in HIV infection than
their naïve counterparts, we also separately co-cultured memory CD4+ T cells with HIV+Sn/DC
[81]. Relative to mDC cultured either with medium (medium/DC), supernatant from HIV
untreated epithelial cells, HIV-Sn, (HIV-Sn/DC) or polyI:C (PolyI:C/DC), both rTSLP-treated
DC (rTSLP/DC) and HIV+Sn/DC induced significant expansion of both naïve and memory
CD4+ T cells by day 7 (Fig. 3.11a and b). Increases in the numbers of CD4+ T cells on day 7,
as determined by enumerating the total viable cells using the Trypan-blue dye exclusion
method, were 1.8-fold for naïve CD4+ T cell co-cultures with HIV+Sn/DC and 3.04-fold for
those with rTSLP/DC. We observed a 4-fold increase for memory CD4+ T cells co-cultured
with HIV+Sn/DC and 4.5-fold for those with rTSLP/DC. To rule out any activity from trace
amounts of HIV that may be present within the HIV+Sn despite thorough washing of HIVexposed epithelial cells, we treated mDC with supernatants from epithelial cells exposed to
AT2-treated virus (AT-2+Sn) in parallel with untreated virus (AT-2-Sn) and observed that AT2+Sn/DC as well as AT-2-Sn/DC induced expansion of naïve CD4+T cells by 3.9 and 4 fold,
respectively by day 7 (Fig. 3.11d). Additionally, we confirmed the significant level of CD4+ T
cell proliferation in co-cultures with rTSLP/DC and HIV+Sn/DC, compared to that with
medium/DC and HIV-Sn/DC, respectively by employing the [3H]thymidine incorporation assay
(Fig 3.11c). A key feature of TSLP-DC is their ability to not only promote homeostatic
proliferation of the autologous CD4+ T cells, but also to induce their differentiation to be
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inflammatory Th2 cells that produce the inflammatory cytokine TNF-α in addition to the
traditional Th2 cytokines IL-4, IL-5, IL-13 [80]. We observed high levels of expression of
each of these cytokines, but not IL-10 or IFN-γ in the CD4+ T cells co-cultured for 7 days with
HIV+Sn/DC or rTSLP/DC (Fig. 3.12). Addition of HIV-1IIIB to the naïve and memory cocultures at the beginning of the culture period resulted in significant increases in infection, as
determined by the analysis of the reverse transcriptase (RT) activity, with HIV+Sn/DC and
rTSLP/DC when compared to respective control co-cultures of HIV-Sn/DC, PolyI:C/DC and
medium/DC (Fig. 313a and b). The relative levels of increased HIV infections amounted to
3.2- and 3.4-fold by day 7 in the co-cultures of naïve T cells with HIV+Sn/DC and rTSLP/DC
and 14 and 43-fold in the co-cultures of memory T cells with HIV+Sn/DC and rTSLP/DC,
respectively compared to that with HIV-Sn/DC or medium/DC. In each case, the effects of
TSLP activated DC on expansion as well as HIV infection of the naïve autologous CD4+ T
cells could be blocked by including neutralizing TSLP antibodies during the co-culturing.
Similar results showing increased infection of co-cultured T cells were observed when HIV1YU2, an R5 strain of HIV-1 was used (Fig. 3.13c).
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Fig. 3.11: mDC activated by HIV-induced TSLP from epithelial cells promote autologous
CD4+ T cell proliferation.
Highly purified autologous naïve or memory CD4+ T cells were co-cultured with mDC that
were activated by pre-incubating with the culture medium (Medium/DC), rTSLP (rTSLP/DC),
or supernatants collected from C33A cells treated with or without HIV-1IIIB (HIV+Sn/DC and
HIV-Sn/DC, respectively). Proliferation in terms of increased numbers of viable cells on day 7
were determined by Trypan blue dye-exclusion for the naïve and memory CD4+ T cells (panels
a, and b, respectively). Proliferation of naïve CD4+ T cells was also observed as determined by
the standard [3H]thymidine incorporation assay (c). Naïve autologous CD4+ T cells co-cultured
with mDC that were activated by pre-incubating with supernatants of epithelial cells exposed to
AT2-treated noninfectious HIV (AT2+sup/DC) or infectious HIV AT2-sup/DC) also
demonstrated increased numbers of viable cells on day 7 as determined by Trypan blue dyeexclusion (d). Error bars represent standard deviation values for triplicate cultures, and data
shown are representative of multiple experiments.

58

59

PolyI:C/DC

HIV-Sn/DC + a-TSLP

HIV-Sn/DC

8

HIV+Sn/DC + a-TSLP

HIV+Sn/DC

rTSLP/DC + a-TSLP

rTSLP/DC

12

Medium/DC + a-TSLP

a

Medium/DC

+
Naïve
cell numbers
7 (x10e4)
CD4+CD4
T cellT numbers
dayday
7 (x10e4)

Figure 3.11:

14

*P=0.03

10

*P=0.05

6

4

2

0

+
Memory
cell numbers
7 (x10e5)
CD4+ TCD4
cell TNumbers
Day day
7 (10e5)

b
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Medium/DC

rTSLP/DC

60

HIV+Sn/DC

HIV-Sn/DC

c
w/o Antibody

2000

w/ Antibody

[3H] Thymidine Incorporation (cpm/0.1ml)

1800
1600
1400
1200
1000
800
600
400
200
0
Medium/DC

d

TSLP/DC

HIV+Sn/DC

HIV-Sn/DC

CD4+ T Cell numbers day 7 (x10e4)

14
12
10
8
6
4
2
0
Medium/DC

rTSLP/DC

61

AT2-Sup/DC AT2+Sup/DC

Fig. 3.12:

mDC activated by HIV-induced TSLP from epithelial cells promotes

differentiation of the naïve CD4+ T cells to inflammatory Th2 cells. Naïve autologous
CD4+ T cells were co-cultured with mDC that were activated by pre-incubating with the culture
medium (Medium/DC), rTSLP (TSLP/DC), polyI:C (PolyI:C/DC) or supernatants collected
from C33A cells treated with or without HIV-1IIIB (HIV+Sn/DC and HIV-Sn/DC, respectively).
After 7 days, the T cells were analyzed for the induction of different cytokines by real-time
quantitative RT-PCR and the fold increase with each treatment, relative to that in medium only
control cultures is shown as average with standard deviation of triplicate values.
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Figure 3.12:

Fold Increase (cytokine mRNA Expression)

80

IL-4

IL-5

IL-13

TNF-α

INF-γ

IL-10

70

60

50

40

30

20

10

0
Medium/DC

rTSLP/DC

HIV+Sn/DC

63

HIV-Sn/DC

PolyI:C/DC

Fig. 3.13: mDC activated by HIV-induced TSLP from epithelial cells promote increased
HIV infection of co-cultured CD4+ T cells.
Autologous naïve or memory CD4+ T cells were co-cultured with mDC that were activated by
pre-incubating with the culture medium (Medium/DC), rTSLP rTSLP/DC), or supernatants
collected from C33A cells cultured with or without HIV-1IIIB (HIV+Sn/DC and HIV-Sn/DC,
respectively). Co-cultures were also incubated with the X4 viral strain, HIV-1IIIB for seven
days and the amount of virus produced in to the supernatants was measured by estimating the
reverse transcriptase (RT) activity on day 7 in naïve CD4+ T cells (a) and memory CD4+ T cells
(b). Similar increases in infection were observed in co-cultures infected with the R5 viral
strain, HIV-1YU2 (c). Error bars represent standard deviation values for triplicate cultures, and
data shown are representative of multiple experiments.
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Higher expression of HIV co-receptors on CD4+ T cells co-cultured with myeloid DC
activated by TSLP from HIV exposed epithelial cells
It has previously been reported that Th2 polarized CD4+ T cells express more
chemokine receptors resulting in enhanced HIV-1 replication [82].

Since there was an

observed increase in viral replication in CD4+ T cells co-cultured with mDC activated by TSLP
from HIV exposed epithelial cells, the cells were examined for chemokine receptor expression.
As shown by mRNA analysis, relative to that of CD4+ T cells co-cultured with DC treated
either with medium (medium/DC), HIV-Sn (HIV-Sn/DC) or polyI:C (polyI:C/DC), both
rTSLP-treated DC (rTSLP/DC) and HIV+Sn/DC induced a 108 and 85 fold increase in the
expression of CXCR4 as well as 60 and 52 fold increase in the expression of the CCR5
chemokine co-receptor of HIV (Fig. 3.14).
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Fig. 3.14: mDC activated by HIV-induced TSLP from epithelial cells promotes higher
expression of chemokine co-receptors on co-cultured CD4+ T cells. Naïve CD4+ T cells
were co-cultured with mDC that were activated by pre-incubating with the culture medium
(Medium/DC), rTSLP (TSLP/DC), polyI:C (PolyI:C/DC) or supernatants collected from C33A
cells cultured with or without HIV-1IIIB (HIV+Sn/DC and HIV-Sn/DC, respectively). After 7
days, the T cells were analyzed for chemokine co-receptor expression by real-time quantitative
RT-PCR. Error bars represent standard deviation values for triplicate cultures, and data shown
are representative of multiple experiments.
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Specific Aim 3:

Investigate the mechanism of HIV-mediated induction of TSLP

expression in epithelial cells.
Results
Transcriptional activation of the human TSLP promoter by HIV includes NFкB
activation
It has recently been shown that TSLP expression in the airway epithelial cells can be
induced by pro-inflammatory mediators (IL-1 , TNF- ) and agonists for toll-like receptors 2, 8
and 9 (TLR2, TLR8, and TLR9, respectively), via the induction of NF B through an NF B
binding site identified within the human TSLP (hTSLP) promoter [69]. In collaboration with
Dr. Shao-Cong Sun’s laboratory in our department of immunology at the UT MD Anderson
Cancer Center, Houston, TX, I investigated whether the mechanism by which HIV induces
TSLP expression in epithelial cells involves NFкB signaling. The cervical epithelial cells
(C33A) were transfected with a luciferase reporter plasmid encoding the full length hTSLP
promoter which contains a wild-type NFкB binding site 3.7 kb upstream of the start of
transcription (TSLP-luc), or a mutated NFкB binding motif (TSLPΔкB-luc) constructed by
site-directed mutagenesis as described previously [69[83]].

The transfected cells were

incubated with HIV or IL-1β and TSLP mRNA expression and luciferase activity were
determined. When compared to medium alone, HIV was able to induce an increase in TSLP
mRNA expression (309-fold) as well as the hTSLP promoter activity (178-fold) at levels
similar to those of the cells stimulated with the positive control IL-1β (Fig. 3.15a and b). On
the other hand, both TSLP mRNA expression and the luciferase activity were unchanged in
C33A cells transfected with the mutated NFкB binding site construct suggesting that HIV
induced TSLP expression involves the NFкB signaling (Fig. 3.15a and b). Additionally,
retroviral vectors expressing an NF-kB super-repressor, IκBαSS/AA, or a control sequence
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pMIGR1 were constructed and transfected into C33A cells to derive C33A-IκBαSS/AA and
C33A-pMIGR1 cell lines, respectively [83]. Expression of IκBαSS/AA, but not pMIGR1,
resulted in the abrogation of TSLP expression in response to HIV as well as IL-1β in these cells
(Fig. 3.15c). Together, these results confirm the role of the NFкB signaling pathway in the
transcriptional activation of HIV induced TSLP expression.
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Fig. 3.15: Transcriptional Activation of the Human TSLP promoter by HIV involves
NFкB signaling. The cervical epithelial cells (C33A) were transfected with a Luciferase
reporter plasmid encoding human TSLP promoter harboring either the wild-type NFкB binding
site (hTSLP-luc) or the mutated NFкB binding site (TSLPΔкB-luc) and exposed to HIV-1IIIB
and IL-1β. Significantly increased levels of TSLP mRNA, assessed by quantitative real time
PCR (a), and Luciferase activity (b) were detected after exposure to HIV-1IIIB and IL-1β when
compared to untreated cells (medium) in cells transfected with hTSLP-luc plasmid but not
TSLPΔкB-luc. Panel c shows TSLP expression, as determined by real-time PCR, in response
to HIV-1IIIB or IL-1β was significantly reduced in C33A cells trasnsfected with a retroviral
vector expressing an NFκB super-repressor, IκBαSS/AA, (C33A-IκBαSS/AA), but not in
those transfected with a control vector, pMIGR1, (C33A-pMIGR1) or untreated control
cultures (medium). Error bars represent standard deviation values for triplicate cultures, and
data shown are representative of multiple experiments.
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Figure 3.15:
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The scavenger receptor gp340 expressed on epithelial cells is necessary for HIV-induced
TSLP expression
We investigated the mechanism underlying the HIV interaction with epithelial cells to
induce TSLP expression. Specifically, we determined the epithelial cells surface molecules
necessary for interaction with HIV.

Recent reports implicated the epithelial cell surface

scavenger receptor gp340, a splice variant of the human protein, the Deleted in Malignant Brain
Tumors I (DMBT1), to bind to the HIV envelope protein gp120 and facilitate
transcytosis/endocytosis of the virus [21, 84]. We reasoned that such interaction with the virus
may be necessary for TSLP expression by the epithelial cells. First, a variety of epithelial cell
lines were screened for cell surface expression of gp340 by flow cytometry. Cervical (C33A),
intestinal (HT-29), and neuronal (SKNMC) epithelial cells, which we observed earlier to
secrete TSLP in response to HIV exposure, showed detectable levels of cell surface gp340 (Fig.
3.16a), with one exception, the pharyngeal epithelial cells (Fadu), which did not express gp340
(Fig. 3.16a). To determine the role played by the epithelial cell surface protein gp340 in TSLP
induction by HIV, gp340 expressing human cervical epithelial cells (C33A) and gp340- null
pharyngeal epithelial cells (Fadu) were cultured with HIV and the cell extracts analyzed for
TSLP expression. High levels of TSLP mRNA as measured by quantitative RT-PCR were
detected in the C33A cells but not the Fadu cells (Fig. 3.16b). Furthermore, the HIV-induced
TSLP expression in C33A cells could be blocked with an antibody to gp340 (Fig. 3.16b). Both
Fadu cells and C33A cells produced TSLP mRNA in response to the positive controls PolyI:C,
TNF-α, and IL-1β, suggesting the specificity of gp340 for HIV-induced TSLP expression(Fig.
3.16b). To begin elucidating the signaling for HIV-induced TSLP expression, the C33A cells
were transfected with a reporter plasmid expressing luciferase under the control of the human
TSLP(hTSLP) promoter followed by incubation with HIV, which resulted in high levels of
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luciferase activity that were blocked when the transfected cells were pre-incubated with gp340
antibody prior to HIV exposure (fig. 3.16c). To further confirm the role of gp340 in HIV
induced TSLP expression, we established a variant of the Fadu cell line that expresses a cellsurface associated form of gp340 by transfecting cells with a plasmid encoding the full length
form of DMBT1 (Fig. 3.16d). Gp340 expression in the transfected Fadu cells was confirmed
by flow cytometry and RNA analyses, and when these cells were cultured with HIV, TSLP
expression was detected as measured by quantitative RT-PCR (Fig. 3.16e). The effect of
gp340 silencing on HIV-induced TSLP production was also determined by knocking down
gp340 expression in C33A cells with siRNA specific to gp340,which resulted in negligible
levels of gp340 detectable in the knock down cells measured in terms of quantitative RT-PCR
as well as flow cytometry (Fig. 3.16 d and e). The C33A cells with the gp340 knocked down,
when cultured with HIV showed significantly reduced levels of TSLP expression as measured
by quantitative RT-PCR (Fig. 3.16f).
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Fig. 3.16: Gp340+ epithelial cells produce TSLP in response to HIV. Surface expression of
gp340 was observed on the cervical epithelial cells (C33A), neuronal epithelial cells (SKMN),
and intestinal epithelial cells (HT-29) but not pharynx-derived epithelial cell line (Fadu)
assessed by flow cytometry using a mouse gp340-specific antibody (A). The red histograms
represent specific staining for gp340 and the blue histograms represent the isotype control
staining, and the numbers in each panel indicate the mean flrouresence intensity (MFI). High
levels of TSLP mRNA were detected in the cervical epithelial cells (C33A) cultured with HIV1IIIB which was specifically blocked by anti-gp340 antibody, while the Fadu epithelial cell line
exposed to HIV did not show TSLP expression. Both C33A and Fadu cell lines produce TSLP
in response to polyI:C, TNF-α and IL-1β (B). Increased levels of luciferase activity were
detected in C33A cells transfected with a wild-type human TSLP promoter luciferase-reporter
plasmid and exposed to HIV-1IIIB, which was specifically blocked by anti-gp340 antibody,
when compared to medium alone or with cells treated with the gp340-specific antibody and not
exposed to HIV (C). Surface expression of gp340 was observed on wild type C33A and Fadu
cells transfected with gp340 but not in wild type Fadu or C33A cells where gp340 was knocked
down as assessed by flow cytometry using a gp340-specific antibody (D). The red histograms
represent specific staining for gp340 and the blue histograms represent the isotype control
staining, and the numbers in the panels indicate the MFI values. Expression of gp340 and
TLR3 in wild type C33A and gp340 knockdown C33A cells and wild type and gp340transfected Fadu cells was assessed by RT-PCR (E). High levels of TSLP mRNA were detected
in gp340 expressing C33A and Fadu cells cultured with HIV. All cell types expressed TSLP in
response to polyI:C (F).

Data shown are averages with standard deviation values of a

representative of multiple experiments with similar results.
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Binding of HIV gp120 to gp340 in epithelial cells is necessary but not sufficient for HIVmediated TSLP expression in epithelial cells
Since we and others have shown that the HIV receptors CD4, CXCR4, and CCR5 are
not expressed on human genital epithelial cells [21, 35] (Table 2), we investigated whether
gp340 on the epithelial cell surface would be necessary and sufficient for inducing TSLP
expression in response to HIV. In 2007, Stoddard et al. showed that gp340 expressed on
human genital epithelial cells binds HIV-1 envelope protein, specifically involving the V3 loop
region for potential viral endocytosis and/or transcytosis in the epithelial cells [21].

To

evaluate the potential role of gp340 interaction in HIV induced TSLP expression, we examined
binding of gp340 on the C33A cells with the envelope protein on HIV-1 virions or the
recombinant HIV-1 envelope protein gp120. Specific wells within the 96-well plates were
coated with either HIV-1, recombinant gp120, anti-gp340, anti-TNFR antibody, or the
appropriate isotype control antibodies (the latter two reagents as positive and negative control
reagents, respectively, because TNFa can induce TSLP expression in epithelial cells, [69]. The
C33A cells were seeded in the coated wells and after overnight incubation the cell extracts
were prepared and analyzed for TSLP expression, in comparison to cross linking TNF on these
cells with TNF-receptor antibody. Neither HIV, recombinant gp120, nor anti-gp340, used for
gp340 cross linking, induced TSLP expression as compared to the positive control treatment
(Fig. 3.17). These data, combined with our earlier results showing TSLP expression in gp340
containing but not gp340-null epithelial cells, suggest that HIV binding to the gp340 receptor is
necessary but not sufficient to produce the signal needed to induce TSLP expression.
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Table 2: Flow cytometry analyses of HIV binding and entry receptors on different cells

Cell line

CD4 Expression
(MFI)

CXCR4 Expression
(MFI)

CCR5 Expression
(MFI)

C33A

0.14

0.92

0.22

Ghost X4

91.58

89.81

-

Ghost Hi5

38.92

3.6

53.6

SKMN

0.44

0.11

0.05

PBMC

42

41.2

52.30
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Fig. 3.17: Gp340 binding does not signal TSLP expression in the epithelial cells. TSLP
production was detected in cervical epithelial cells (C33A) after cross linking TNF receptor
with an antibody to TNF-R when compared to medium alone or cells where the surface gp340
was bound to with immobilized HIV, recombinant gp120, or cross-linked to an antibody to
gp340. Data shown are average with standard deviation values of a representative of three
separate experiments.
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Figure 3.17:
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Endocytosis of HIV-1 mediated by gp340 on epithelial cells induces TSLP expression
The gp340 on the epithelial cell surface was also identified in 2002 by Cannon et al to
be endosome-associated leading to the suggestion that gp340 may be capable of trafficking to
intracellular compartments [84]. Based on our results showing that gp340 on the epithelial
cells is necessary but not sufficient for HIV-induced TSLP expression, we investigated by
transmission electron microscopy whether gp340 expressed on the C33A cells could be
involved in the endocytosis of HIV-1. Cells and virus were pre-incubated at 4ºC for two hours
and then transferred to 37ºC for various time intervals. Samples collected at the different time
point were processed and examined using electron microscopy. Fig. 3.18, shows a selection of
the C33A cell culture incubated with HIV and a single cell with an enlarged subsection
containing the virus particles inside the endosomes. A similar analysis showed no virus
particles within endosomal compartments in the gp340 null Fadu cell line. This data suggests
that virus is internalized into the endosomes of the gp340 positive cells even though these cells
do not show CD4, CXCR4, and CCR5 surface expression required for productive infection by
HIV (Table 2). To further confirm the requirement for endocytosis of HIV to induce TSLP
expression, the gp340-positive C33A cells were cultured with HIV in the presence or absence
of several different types of inhibitors of endocytosis: Dimethyl amiloride (DMA), which
inhibits macropinocytosis;

Cytochalasin D (CCD), which blocks endocytic trafficking

including clatherin-mediated entry; Chlorpromazine, which blocks clatherin-coated pitmediated endocytosis [85]. Cells were cultured with HIV in the presence of these various
endocytosis inhibitors and the cell extracts were analyzed for TSLP. Treatment with DMA,
CCD, and chlorpromazine reduced TSLP expression as measured by quantitative RT-PCR
analysis of the mRNA (Fig. 3.19a) and by ELISA for the protein in the cell extract (Fig. 3.19b)
suggesting that endocytosis of HIV into the C33A cells leads to induction of TSLP expression.
85

The toll-like receptors (TLRs) 3, 7, 8, and 9, which sense pathogens and initiate signaling, have
been shown to localize within the endosomal compartment [85-87]. For single-stranded RNA
viruses, a class to which HIV belongs to, TLRs 7 and 8 are important mediators of pathogenspecific RNA recognition and immune activation [86, 87]. Reduction of TSLP expression in
response to the TLR7/8 ligands CL097 and CL075 was observed in both C33A and Fadu cells,
and in response to HIV in the C33A cells, when treated with DMA, CCD, and chlorpromazine
suggesting that activation of the intracellularly located toll like receptors TLR7 or TLR8 may
be involved in HIV-mediated TSLP expression in the gp340+ C33A cells (Fig 3.19a).
Therefore, we examined whether acidification of the endosomes is necessary for HIV RNA
within the endosomes to interact with TLR7/8 and induce TSLP expression. Specifically, we
tested two weak bases, chloroquine and quinacrine, that neutralize the acidic environment of
endocytic vesicles along with another endosomal acidification inhibitor bafilomycin A1
(BFLA-1) which acts on vacuolar H+-ATPases [85]. We observed that all three inhibitors were
able to reduce TSLP expression in response to HIV as well as the specific ligands CL097 and
CL075 to TLR7 and 8, respectively (Fig. 3.19a) suggesting that endocystosis of HIV-1
followed by acidification of the endosome is involved in HIV induced TSLP expression in
these gp340+ cervical epithelial cells.
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Fig. 3.18: Endocytosis of HIV into epithelial cells. Transmission electron microscopy
(TEM) analyses of gp340+ C33A (a) and gp340- Fadu (b) cells exposed to HIV. Enlargement
of the framed area from within the C33A cell exposed to HIV for 20 minutes at 37º C shows a
virus particle with electron dense core structure typical of HIV within an endosome of the cell
(a) while a similar analyses of an area with a dark spot in the HIV-exposed Fadu cells showed
nonspecific particles that exhibited no organized structure (b).

87

Figure 3.18:
a

b
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Fig. 3.19: Gp340 receptor mediated endocytosis of HIV triggers HIV induced TSLP
experession. Pretreatment of gp340+ cervical epithelial cells (C33A) with various inhibitors of
endocytosis (shown on the x-axis) reduced HIV induced TSLP expression (a). Both gp340+
C33A and gp340- Fadu cells produced TSLP in response to the TLR7/8 ligands CL075 and
CL097 which was reduced in the presence of the various inhibitors of endocytosis (a). Protein
analysis by ELISA in the cell extracts or culture supernatants of cells treated with various
endocytosis inhibitors and exposed to HIV or TLR7/8 ligands confirmed the reduction of TSLP
production in the C33A cells (b).
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HIV-1 RNA is responsible for inducing TSLP expression in gp340+cells
Both TLR7 and TLR8 are localized in the endosomes within the cell cytoplasm and
endosomal acidification is required for ligand recognition and signaling by these TLRs [86,
87]. Single stranded RNA (ssRNA) containing viruses that signal through these TLRs enter
cells through endocytosis and are held in the endosomal compartment where pH changes
induce degradation of the viral particles allowing the viral nucleic acid to come into contact
with TLR7 or TLR8 [91]. The structural and functional features of TLR7 and 8 show a high
degree of phylogenetic similarity with both receptors capable of recognizing the guanosine and
uridine rich ssRNAs derived from HIV [91]. Since we observed endosomal acidification to be
involved in HIV induced TSLP expression we tested whether a synthetic oligonucleotide
corresponding to the HIV-1 RNA would induce TSLP expression. We cultured the gp340+
C33A and gp340- Fadu epithelial cells with RNA40 (a synthetic [G+U] rich short
oligoribonucleotide corresponding to the U5 region of HIV-1). To facilitate uptake into the
cells, RNA40 was pre-inucbated with DOTAP (liposomal transfection delivery system) prior to
adding to the cells, and TSLP expression was observed, in terms of RNA as well as protein, in
both C33A and Fadu cells but not when the negative control RNA41 was introduced with
DOTAP (Fig. 3.20a and b). Furthermore, the gp340- Fadu cells that do not express TSLP in
response to HIV, when cultured with HIV pre-incubated with DOTAP, to bypass the receptor
mediated endocytosis, exhibited TSLP expression (Fig. 3.20a) suggesting that gp340-mediated
entry of HIV into the endosomes for HIV-induced TSLP expression.
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Fig. 3.20: HIV RNA stimulates TSLP production in epithelial cells. C33A and Fadu cells
were cultured with HIV, RNA 40 and RNA 41, each mixed with DOTAP, and the positive
control Poly I:C followed by the analyses of TSLP mRNA expression by qPCR (a). Both
C33A and Fadu cells cultured with HIV-1 mixed with DOTAP showed TSLP expression (a).
Protein analysis (ELISA) of C33A and Fadu cells cultured with HIV and RNA40 and
RNA41mixed with DOTAP showed TSLP production only with RNA40 (b).
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TLR activation as potential mechanism for HIV-induced TSLP expression
To more directly investigate the role of TLR7/8 in signaling for HIV-induced TSLP
expression in epithelial cells we first determined whether C33A and Fadu cells express TLR7
and TLR8 by RT-PCR analysis (Fig 3.21a). Both C33A and Fadu cells were found to express
TLR7 and TLR8 in comparison to the TLR7 positive control pDC cell line Gen 2.2 and the
TLR8 positive control mDC [87]. We employed siRNA mediated knock down of either TLR7
or TLR8 in C33A cells by transecting plasmid constructs corresponding to either the human
TLR 7 or 8 genes, and after 36 hours assessed by RT-PCR the levels of TLR7 and TLR8
expression (fig. 321b). Next we exposed these transfectants, with TLR7/8 genes knocked
down, to HIV along with control reagents and analyzed the cell extracts for TSLP mRNA and
protein. Relative to the control reagents polyI:C and IL-1β, which signal TSLP expression
through TLR3 and IL-1b receptor, respectively and the wild type C33A cells, the C33A
transfectants with TLR7 or TLR8 knocked down showed significantly reduced of TSLP mRNA
as measured by quantitative PCR (Fig. 3.21c) and TSLP protein measured by ELISA (Fig.
3.21d). These results strongly support the involvement of TLR7/8-mediated signaling by HIV
to induce TSLP expression in the gp340-positive genital epithelial cells.
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Fig. 3.21: TLR activation is involved in HIV induced TSLP expression in the epithelial
cells. RT-PCR analysis of TLR7 or TLR8 expression in plasmacytoid dendritic cells (pDC),
myeloid dendritic cells (mDC), and a variety of epithelial cells (a). RT-PCR analysis of TLR7
or TLR8 expression in wild type or knockdown C33A cells (b). TSLP mRNA analysis in wild
type or TLR7 or TLR8 knockdown C33A cells (c). TSLP protein analysis in wild type or
TLR7 or TLR8 knockdown C33A cells.
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Discussion
Genital and oral mucosal tissues are the primary sites of entry and infection by HIV, but
the mechanisms by which the virus crosses the naturally protective barriers of the lower female
genital tract are not clear. Predicted mechanisms for at least trace amounts of virus to enter the
mucosal microenvironment, based on some experimental evidence, include breaches in the
epithelial layers, virus capture by the Langerhan’s cells beneath the epithelium, or endocytosis
of the virus through the epithelium. Nevertheless, a major portion of even the limited amount
of virus that penetrated the epithelial barrier will perish in the harsh mucosal microenvironment
filled with antiviral factors and low pH. In fact, studies from the nonhuman primate model
showed that within the first 3-4 days of oral or vaginal exposure only a small number of
infected cells can be detected in the tonsil and vaginal mucosal tissues, respectively, but the
infection increases in situ as well as spreads rapidly to the distal lymphoid tissues leading to
CD4 cell loss first detectable in the gut at around week 2 post-challenge [14, 19, 88]. These
data suggest that the virus manipulates the tissue microenvironment to not only ensure survival
and infection in situ, but also successfully spread the infection to distal compartments.
Results from this investigation provide strong support for the hypothesis that one way
HIV maneuvers the hostile oro-genital mucosal microenvironment is by increasing the
population of CD4+ T cell targets at the site of viral entry by inducing TSLP production from
the epithelial cells that can activate the surrounding DC/LC for the expansion of the CD4+ T
cells. Supporting evidence was obtained from in vitro studies that showed HIV exposure
induces TSLP production in a variety of epithelial cell lines corresponding to different
anatomical locations as well as primary keratinocytes. Also, consistent with the prevailing
notion that genital epithelial cells cannot be infected by HIV we observed that infectious as
well as non-infectious HIV-1 strains were equally effective to induce TSLP production.
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Results from the present investigation also demonstrated that the TSLP produced by the
epithelial cells is biologically functional in terms of activating myeloid DC characterized by the
expression of the chemokine receptors TARC and MDC that are shown to be important for the
DC to recruit inflammatory Th2 CD4+ T cells to the site of inflammation [58, 80].
Furthermore, evidence was obtained that these CD4+ T cells serve as additional targets for HIV
infection where co-culturing with DC activated by TSLP within the HIV-exposed culture
supernatants induced expansion and differentiation of inflammatory Th2 CD4+ T cells as well
as increased HIV infection which could be blocked in the presence of a neutralizing TSLP
antibody.
In support of the results from in vitro studies showing HIV-induced TSLP production
by epithelial cells, evidence was obtained from the nonhuman primate model where
immunohistochemistry and RNA analyses clearly demonstrated increased production of TSLP
in the vaginal, oral, and rectal tissues of monkeys exposed to SIV and SHIV, respectively.
Furthermore, in situ hybridization analysis of SIV positive cells as well as the measurement of
plasma viremia levels provided correlation between increased TSLP expression and viral
infection within the vaginal mucosa. Finally, studies employing the human cervical exlpant
model further corroborated the critical role of HIV-induced TSLP where RNA and confocal
microscopy analyses showed increased production of TSLP in epithelial tissue after HIV
exposure. It is believed that once DC are activated, they migrate to the draining lymph node
where they trigger the proliferation of naïve CD4+ T cells. Previous studies performed in the
vaginal explant model have demonstrated that langerhans cells and CD4+ T cells can interact in
the vaginal epithelium providing a means for T cell expansion to occur directly at the site of
infection [20].
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It has been reported that antiviral CD8 T cell responses were generated within the
vaginal mucosal tissues, but at a slower rate and to a much lower level compared to the peak
viral loads and that this trend was even more pronounced in the gut [89]. Based on these
observations, it has been suggested that the antiviral immunity, as measured by analyzing for
CD8 T cell response is “too little and too late” to provide protection in terms of clearance of
infection and prevention of CD4+ T cell loss. However, it is not clear what changes within the
mucosal microenvironment subsequent to viral exposure facilitate kinetics of virus infection
over that of antiviral host immune responses. Data from the present investigation showed that
the kinetics of virus-induced TSLP expression paralleled SIV infection within the vaginal
tissues over the first two weeks post-infection and also coincided with an increase in the
numbers of CD11c+ mDC and CD4+ T cells. These data, together with the results from in vitro
studies support HIV-induced TSLP production by the mucosal epithelial cells as a critical event
for DC-mediated expansion and HIV infection of CD4+ T cells, which secrete inflammatory
cytokines and avoid/delay generation of appropriate host antiviral responses necessary for
protection during vaginal HIV transmission.
The significance of the present investigation lies not only in providing evidence for
HIV-mediated TSLP production by the genital epithelial cells as an important means for the
virus to successfully manipulate the mucosal microenvironment, but also uncovered the
underlying mechanism by which HIV-1 transmits signals in the epithelial cells for TSLP
expression. Multiple lines of evidence were obtained in support of HIV interaction with gp340
on human cervical epithelial cells to be important for TSLP expression, including gp340blocking antibody as well as gp340 gene knock down to inhibit TSLP production as well as the
inability of HIV to induce TSLP expression in gp340-null cell line Fadu that was corrected by
gp340 gene transfection[21]. Furthermore, HIV RNA endocytosed into gp340+ epithelial cells
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was shown to induce TSLP expression through TLR7/8-mediated signaling and NFkB
transcription factor activity. The possibility that gp340 could facilitate endocytosis of HIV was
explored in studies employing transmission electron microscopy where gp340 expressing C33A
cells exposed to HIV exhibited endosomes with electron dense particles resembling viral core
structure while the gp340 null cell line (Fadu) did not show endosomal HIV particles. It is
known that TLR7 and TLR8 recognize ssRNA viruses [86, 87] and are located within the
endosome.

Knockdown of TLR7 or TLR8 in the gp340+ C33A cervical epithelial cells

resulted in a reduction in HIV-induced TSLP expression. Both TLR 7 and TLR 8 receptors
have been shown to be upstream activators of the NF-kB signaling pathway [69] and HIVmediated TSLP expression was abrogated when mutations were introduced into the NF-kB
sequence in the human TSLP promoter or in the presence of a dominant repressor of NF-kB.
Historically, the role of TSLP has been documented in the study of allergic diseases, but
this investigation showed that TSLP also plays an important role in the acute phase of HIV-1
infection by creating conducive environment for the virus in sustaining the small dose of the
initial virus inoculum that crosses the mucosal barrier. This raises the possibility of targeting
TSLP as a novel strategy to block mucosal HIV-1 transmission.
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CHAPTER 4
Future Directions
Sexual transmission is the major route of human immunodeficiency virus type 1 (HIV1) infection worldwide, most occurring in developing countries [13, 72-75].

Unless

preventative measures are taken, the number of infected cases will continue to grow. While
vaccination is the most effective tool in preventing the spread of HIV, no suitable vaccine
candidate is currently available. Since women acquire the majority of all new HIV infections,
it is imperative to prevent or substantially reduce virus transmission by developing methods
that are safe, effective, economical, and more importantly can be controlled by women. One
such method is the use of topical microbicides that would be able to prevent HIV-1 entry
through the genital mucosa. Methods of delivery could be as a gel, cream, sponge, film,
suppository, ring or diaphragm. Such treatment could be applied before sexual intercourse to
prevent HIV transmission. An important aspect of the preclinical path to developing anti-HIV
therapeutic/vaccine/microbicide candidates is the use of suitable animal models where safety as
well as efficacy can be demonstrated. Among the strategies for HIV microbicide development
currently being pursued by many groups around the globe, are inhibitors of virus replication
targeting the virus-encoded reverse transcriptase and/or the protease enzymes or virus entry
inhibitors targeting the binding and/or fusion of HIV-1 with the host cell membrane once it
crosses the mucosal epithelium and comes in contact with CD4+ target cells. The present
investigation identified a novel target that could prevent the recruitment of target cells to the
site of infection, thereby letting the natural protective barrier of the mucosal microenvironment
curtail virus survival and viral spread to distant compartments. This study has shown the
importance of TSLP produced by genital epithelial cells in response to HIV exposure and how
TSLP helps HIV-1 to overcome the barriers of the mucosal microenvironment to successfully
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invade its host. TSLP should therefore be considered as a target for intervention in the
prevention of HIV-1 infection. It has been established that TSLP is expressed in a “steadystate” by epithelial cells [90]. Using immunohistochemical analysis in the rhesus macaque
model, this study demonstrated that the over expression of TSLP after viral exposure leads to
inflammatory responses resulting in increased CD4+ T cell targets available for HIV to not
only ensure its survival in the local hostile environment but also aid in its spread to distal
compartments. Therefore any intervention strategy should be aimed at the prevention of the
over expression of TSLP in response to HIV exposure. Since HIV induced TSLP expression
signals through NFκB, it would seem likely to target NFκB to inhibit HIV-induced signaling
for TSLP expression but NFκB can be activated by exposure of cells to a variety of outside
stimulants such as lipopolysaccharide (LPS) via toll like receptor (TLR) activation, or
inflammatory cytokines such as TNF or Interleukin-1 (IL-1), growth factors, lymphokines,
oxidant-free radicals, inhaled particles, viral infection, including HIV-1, B or T-Cell activation,
and by other non-specific stimuli [91, 92]. Since NFκB activation includes such a broad range
of stimulants, a more specific target would be the nuclear receptors retinoid x receptors (RXR)
α and β since their binding sites have been identified within the human TSLP gene promoter.
In this regard, it has recently been reported that selective ablation of retinoid X receptors alpha
and beta (RXRα and RXRβ, respectively) in mouse epidermal keratinocytes results in the
development of chronic dermatitis similar to that observed in human atopic dermatitis (AD)
patients, and this is associated with significant increases in the TSLP expression levels [70].
This suggests that these nuclear hormone receptors function as negative regulators of TSLP
raising the interesting prospect of using RXR agonists as a unique strategy for targeting HIVinduced TSLP production. All-trans retinoic acid (ATRA) serves as the major ligand for the
retinoid X receptors (RXRs), in particular the isomer 9-cis-retinoic acid (9-cis-RA) has been
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shown to be a high affinity ligand for this receptor [93, 94]. Therefore, 9-cis-RA treatment of
mucosal vaginal tissues could be a potential strategy against HIV-induced TSLP production.
Preliminary data revealed strong inhibitory effects of 9-cis-RA on HIV induced TSLP
expression (fig. 4.1).
Another potential therapeutic approach specifically targeting TSLP induction by HIV in
genital epithelial cells is the designing of microbicides to block the epithelial cell receptor
gp340 necessary for HIV-induced TSLP expression. A potential candidate for this method
would be the gp340 antibody. Expression of gp340 has been detected in vaginal tissues and
data from this study revealed that pretreatment of epithelial cells with αgp30 prior to HIV
exposure resulted in a reduction in HIV induced TSLP expression (Fig. 3.16a).

Vaginal

delivery of this antibody could block viral binding thereby preventing an exacerbation of TSLP
expression-mediated recruitment and infection of CD4+ T cells. Continued use of the antibody
could also potentially reduce female to male transmission of HIV-1 since αgp340 could bind to
a variety of HIV-1 strains found in vaginal secretions. Since this antibody binds to a well
conserved portion of the viral envelope, the possibility for the development of resistant strains
of HIV-1 is diminished.
Studies of the effectiveness of 9-cis-RA and αgp340 in both the cervical explant and rhesus
macaque models could provide a framework for the clinical development of suitable inhibitors
of HIV-induced TSLP expression.
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Fig. 4.1: 9-cis-RA inhibition of TSLP expression. Cervical epithelial cells (C33A) were
incubated in the presence or absence of 9-cisRA with either HIV-1IIIB, polyI:C, or IL-1β for 1218 hr. TSLP expression, measured in terms of mRNA analyses by RT-PCR, was completely
abrogated in the presence of 9-cisRA.

106

Fold Increase (TSLP mRNA)

Figure 4.1:

350
300
250
200
150
100
50
0
HIV
9-cis-RA
HIV
polyI:C
IL-1β

+
+
-

polyIC
+
-

+
+
-

107

IL-1β
+
-

+
+

+

CHAPTER 5
Materials and Methods
Cell Culture and Production of Virus Stock: Epithelial cell lines representing cervical
(C33A), neuronal (SKMN), and intestinal (HT29) origin were obtained from ATCC and
maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and the appropriate
antibiotics.

Rhesus macaque epithelial cells (4mBr-5) were obtained from ATCC and

maintained in Hams F12 medium (F12K) supplemented with 2mM L-glutamine, 1.5gm/liter
sodium bicarbonate, 30ng/mouse epidermal growth factor and 10% fetal bovine serum.
Pharyngeal epithelial cells (Fadu) were obtained from ATCC and maintained in EMEM
supplemented with 10% fetal bovine serum and the appropriate antibiotics. Adult normal
human epidermal keratinocytes (NHEK) were obtained from Lonza Biosciences (Walkersville,
MD) and maintained in KGM-2 media. The Ghost X4 cells were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH and maintained in
DMEM supplemented with 10% fetal bovine serum (FBS) and the appropriate antibiotics.
Chronically HIV-infected H9 cells (H9/HIV-1IIIB) were maintained in RPMI-1640 medium
supplemented with 10% FBS. Primary human peripheral blood mononuclear cells (PBMC)
were isolated by the standard Ficoll-Hypaque density gradient separation method from blood
samples purchased from Gulf Coast Blood Center (Houston, Texas). Gen 2.2 (pDC cell line)
and MDC were gifts from Dr. Yong-Jun Liu. A plasmid encoding the HIV-1 proviral DNA
with a deletion in the envelope region, pMenv(-), and another plasmid encoding HIV-1 env
sequence representing clade D virus 93ZR001.3 and the plasmid encoding the full-length
genome of the R5 virus YU2, were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH. The plasmid MD.6 encoding the VSV
envelope glycoprotein was obtained from Dr. Inder Verma, Salk Institute, San Diego, CA. The
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AT-2 treated and untreated HIV-1 strains ADA and MN were obtained from Dr. Jeff Lifson,
Laboratory of Retroviral Pathogenesis, AIDS Vaccine Program, NCI-Frederick Cancer
Research and Development Center, Frederick, MD.
Production of virus stock
Infectious virus stock was prepared from each of the different molecular clones of HIV-1
strains used in the study by transfecting 293T cells with 10 μg of plasmid DNA using the
calcium phosphate method. Briefly, cells were grown to 70-90% confluency in 100mm tissue
culture plates. For preparing the envelope-pseudotyped viruses, plasmid DNA encoding the
env-defective HIV-1 (pMenv-) and the envelope sequences from the VSV or the HIV strain
93ZR001.3 were co-transfected into 293T cells. The infectious HIV-1IIIB was collected from
the supernatants of chronically infected H9/HIVIIIB cells. The culture supernatants containing
infectious virus were collected 48 hours after transfection of the 293 T cells or culturing of the
chronically infected H9/HIV-1IIIB, quantitated by determining the reverse transcriptase activity
or the Multinucleate Activation of Galactosidase Indicator Cells (MAGI) assay and either used
immediately or stored at –80 0C.
Induction of TSLP expression in epithelial cells: Various epithelial cells were seeded at a
density of 1.2 x 106 cells per well in 12-well plates. In cases where ELISA analysis was
performed, cells were seeded at a density of 5.0 x 106. Cells were incubated overnight with
HIV-1IIIB, HIV-1YU2, HIV-193ZR001.3, 10µg/ml LPS (Invivogen, San Diego, CA), 5 µg/ml
PolyI:C (Invivogen, San Diego, CA), 1 ng/ml IL-1β or 10 ng/ml TNFα (R&D systems,
Minneapolis, MN), anti-TNFR (Santa Cruz Biotechnology, Santa Cruz, CA), rgp120
(Immunodiagnostics, Woburn, Ma), CL075 or CL097 (Invivogen), 10 μg/ml RNA40 (ORN
derived from HIV-1 U5 region nt 108–127, GCCCGUCUGUUGUGUGACUC); 10 μg/ml
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RNA41 as a negative control (U to A replacement, in RNA40) (Dharmacon Inc.) formulated
with 12.5 μg/ml DOTAP Liposomal Transfection Reagent (Roche Diagnostics Corp.).
Cross linking of gp340 on epithelial cells for determining the effect on TSLP expression:
Specific wells within the 96-well tissue culture plates were coated with either TNF-R antibody,
its isotype control antibody (Santa Cruz Biotechnology, Santa Cruz, CA), HIV-1IIIB or
recombinant gp120 (Immunodiagnostics, Woburn, MA). The plates were sealed with parafilm
and placed at 4ºC overnight. The following day, the plates were washed and blocked with
200µl of DMEM supplemented with 10% FBS for 30 min at 37ºC. C33A cells were seeded at
a density of 2 x 104 per well. The plates were incubated for 12-18 hr at 37ºC and cells lysed the
following day for RNA analysis.
Determination of HIV Endocytosis into epithelial cells.

The gp340+ C33A cervical

epithelial cells as well as the gp340- Fadu epithelial cells were incubated with HIV-1IIIB or the
TLR7/8 ligands CL075 and CL097 (Invivogen, San Diego, CA) in the presence or absence of
various reagents that are known to inhibit endocytosis and endosomal maturation/acidification:
DMA (50 μM); CCD (10 μM); chlorpromazine (6.25 μg/ml); chloroquine (5 μM); quinacrine
(5 μM); NH4Cl (1 mM); and BFLA-1 (50 nM), all from Sigma-Aldrich (St. Louis, MO).
Following incubation, the cell extracts were prepared and analyzed for TSLP expression by
real-time RT-PCR analyses.
Isolation and culturing of myeloid DC: Buffy coats of blood samples from healthy adult
donors were purchased from Gulf Coast Blood Center (Houston, TX) and the peripheral blood
mononuclear cells (PBMC) were separated by the standard ficoll-centrifugation methodology
to isolate the CD11c+ myeloid DC as previously described[80]. In brief, the DC-enriched
population (lineage-cells) was obtained from PBMC by negative selection using a mixture of
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monoclonal antibodies (mAbs) against the lineage markers, CD3 (OKT3), CD14 (M5E2),CD16
(HB78), CD20 (L27), CD56 (B159), and CD235a (10F7MN) (BD Biosciences), followed by
the use of goat anti–mouse IgG-coated magnetic beads (M-450; Dynal and Miltenyi Biotec).
The CD11c+ and lineage- DC and CD4+ T cells were separately isolated by a FACS Aria sorter
(BD Biosciences) using APC-labeled anti-CD11c (B-ly6), a mixture of FITC-labeled mAbs
against lineage markers including CD3 (SK7), CD14 (MØP9),CD16 (3G8), CD19 (HIB19) and
CD56 (NCAM16.2) (BD Biosciences); and pacific blue-labeled CD4 (OKT4; eBioscience) to
reach >99% purity. The CD11c+ DC were cultured in RPMI containing 10% FBS by seeding at
a density of 1-3×105 cells/well in 200 µl volume in a flat-bottom 96-well plate in the presence
of culture medium alone, 100 ng/ml rTSLP, prepared in-house using an adenovirus vector
system as described previously[64], or supernatants collected from epithelial cells previously
cultured without or with HIV (at an MOI of 0.5 or 600 TCID50 based on MAGI assay and
equivalent to 60,705 cpm of RT activity) and designated as HIV-Sn and HIV+Sn, respectively.
The HIV+Sn contained 100 ng/ml of TSLP protein, as determined by ELISA. For determining
TSLP-specificity of DC activation, a mixture of two neutralizing antibodies (including one
TSLP monoclonal antibody and one rabbit anti-human TSLP polyclonal antibody) were add to
mDC for 30 minutes prior to culturing the cells with culture medium, rTSLP, HIV+Sn, or HIVSn to block the TSLP activity. The neutralizing monoclonal anti-TSLP antibody IgG1 (R&D
Systems) and the polyclonal rabbit anti-TSLP IgG were used at a concentrations 10 and
20µg/ml, respectively along with the corresponding isotype control monoclonal and polyclonal
antibodies at matching concentrations.
DC activation and viability: The CD11c+ myeloid DC cultured with medium, rTSLP, HIV-Sn
or HIV+Sn for 24 h were collected and resuspended in EDTA-containing medium. Viability of
the DC was determined by the standard Trypan blue dye-exclusion method. To determine the
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activation status, the DC were stained with PE-conjugated mouse anti-human mAbs to CD40,
CD80 and CD86 and an IgG1 isotype control (all from BD Biosciences), and analyzed on an
LSR II flow cytometer (BD Biosciences) using flowjo software (version 8.3.4, Tree Star). The
dead cells were excluded from the analyses by using the violet Live/Dead stain kit (Invitrogen).
The DC culture supernatants were collected at 24 h, frozen at -80 °C and analyzed within 3
months with protein ELISA kits for TARC and MDC (R&D Systems, Minneapolis, MN). In
some experiments, RNA samples prepared from the cultured mDC were used for gene
expression analyses.
Isolation of naïve CD4+ T cells: The naïve and central memory CD4+ T cells were isolated
from PBMC on the basis of CD45RA+, CD45RO-, and lineage- phenotype by using a human
CD4+ T cell enrichment cocktail (Stem Cell Technologies) followed by the use of a biotin
labeled CD45RA, an APC-labeled anti-biotin antibody, a mixture of FITC-labeled mAbs
against the lineage markers CD14(MØP9), CD16 (3G8), CD19 (HIB19), CD56 (NCAM16.2),
CD11C (HL3), TCRγδ (V65), PE-labeled mAbs against CD45RO (UCHL1), (all from BD
Biosciences), FITC-labeled BDCA2 (AC144), PE-labeled BDCA4 (AD5-17F6), and PElabeled CD25(4E3) (all from Milteny Biotech) and pacific blue labeled CD4 (OKT4)
(eBioscience) in a FACS Aria sorter (BD Biosciences). The final CD4+CD45RA+CD45ROCD25- or CD4+CD45RA-CD45RO+CD25- lineage- fraction isolated was determined to be >
99% pure.
mDC-CD4+ T cell co-cultures: Activated mDC were co-cultured with 2.5 to 5.0×104 purified
autologous or allogeneic naïve CD4+ T cells (DC:T cell ratio, 1:1 or 1:2) in round bottomed 96well culture plates for 7 days. In some experiments HIV-1IIIB or HIV-1YU2 were added to the
co-cultures overnight, and the cells were washed three times to remove any free viral particles.
The co-cultures were resuspended in RPMI medium containing 10% FBS. The mixture was
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then incubated for 5 minutes in 37oC in 10% FBS-RPMI 1640 and the cells were pelleted by
centrifugation. The cells were subsequently washed three times with 10% FBS-RPMI 1640.
On days 4 and 7, the viable cell counts were determined by the standard Trypan blue dyeexclusion method.

In some cases the co-cultures were pulsed for 16-18 h with 1

Ci

[3H]thymidine on day 6 and then the cells were collected to assess for proliferation in terms of
[3H]thymidine incorporation. In the co-cultures where HIV is added, the relative levels of
infection were determined by assaying for reverse transcriptase (RT) activity in the culture
supernatants.
Animals: Vaginal tissue samples were obtained from rhesus macaques (Macaca mulatta)
infected with SIVmac251 by the vaginal route in a previous study at the California Primate Center
[14].

The animal facilities are fully accredited by the Association for Assessment and

Accreditation of Laboratory Animal Care International, and the study was conducted according
to National Institute of Health Guidelines on Care and Use of Laboratory Animals. Oral and
rectal samples were obtained from rhesus macaques infected with SHIV89.6P and SIVmac251, by
the respective routes from animals housed at the Michael Keeling Center for Comparative
Medicine and Research of The University of Texas MD Anderson Cancer Center, Bastrop TX.
All of the experiments were conducted according to the provisions of the Animal Welfare Act,
PHS Animal Welfare Policy, and the principles of the NIH Guide for the Care and Use of
Laboratory Animals, and the policies and procedures of the University of Texas MD Anderson
Cancer Center.
Tissue collection in the macaque studies and RNA isolation: Collection of vaginal tissues
from animals euthanized at different days post-infection with SIVmac251 was described earlier
[14].

The tonsil and rectal biopsy samples were obtained by standard fenestrated cup

(1.8mmx190 cm) endoscope from animals infected by the oral and rectal routes with
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SHIV89.6P and SIVmac251, respectively. All the tissue samples from the macaques for RNA
analyses were collected and stored in RNAlater at -20°C. At the time of the assay, the tissue
samples were homogenized, and the total RNA was isolated by using the RNeasey Qiagen kit
(Qiagen, Valencia, CA). The purified RNA was used to determine tissue TSLP RNA levels by
real-time quantitative RT-PCR using the rhesus macaque-specific TSLP primers: 5´-CGACAG
CATGGTTCTTCTCA-3´ and 5´-CGATTTGCTCGAACTTAGCC-3´ and the rhesus macaque
specific MDC and TARC primers (Applied Biosystems, Foster City, CA).
In situ hybridization for detection of SIV RNA-positive cells: The in situ hybridization
analysis (ISH) was performed by our collaborators from the California Primate Center, Davis,
CA, on the vaginal tissue sections using
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S-labeled SIV riboprobes as described [95], with

modifications. Radioactive probes had a specific activity of > 3.5 x 108 cpm/ug as determined
by the in-vitro transcription labeling of the SIV gag and env genes. The hybridization solution
contained radiolabeled SIV probes at a total concentration of 1.5 x 106 cpm/100 ul. The
riboprobe cocktail in the hybridization buffer was layered over each tissue section. The slides
were coated with LM-1 autoradiographic emulsion (Amersham) and allowed to develop at 4o C
for 14 days.

Controls for ISH included: 1) matched tissues from SIV-uninfected rhesus

monkeys; 2) tissues from SIV-infected rhesus monkeys with high virus loads (positive control);
3) serial tissue sections hybridized with SIV sense riboprobes and; 4) omission of the probe in
the hybridization mixture.
SIV RNA measurement: Tissue RNA samples were analyzed by our collaborators from the
California Primate Center, Davis, CA, for viral RNA (vRNA) using a quantitative branched
DNA (bDNA) assay and reported as viral RNA copy numbers per ug of total tissue RNA [96].
The detection limit of this assay is 125 copies of vRNA. To evaluate the specificity of the
tissue assay, samples were collected from 3 animals that had not been exposed to SIV [97].
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Excluding one spurious result, average values for the bDNA assay were 113 copies/ug tissues
RNA in the uninfected animals. The cut-off for the assay was 200 copies/ug tissue RNA
average + 2 standard deviation (SD) values. Tissue sample with less than 200 copies of
vRNA/ug total tissue RNA were reported as negative.
Immunohistochemistry: The vaginal tissue sections were analyzed for the expression of
TSLP as well as presence of CD11c+ DC and CD4+ T cells by the personnel in our
departmental immunohistochemistry core facility. The tissue slides were incubated with either
rat anti-human TSLP (mAb 12F3, DNAX, Palo Alto, CA), mouse anti-human CD4 (mAb MT477, BD PharMingen) or mouse anti-human CD11c (mAb AHS1153, Biosource) at room
temperature for 1 h in PBS. The slides were washed with PBS twice and incubated with
biotinylated secondary antibody for 30 min (PK-4004, Vector Laboratories, Burlingame, CA)
before washing and treatment with avidin-peroxidase complex reagents for 30 min (PK-4004,
Vector Laboratories). Subsequently, the slides were washed and incubated with the substrate
SK-4200, which stained red or SK-4100, which stained brown (Vector, Laboratories).
Real-time quantitative RT-PCR: Epithelial cells exposed to different HIV-1 strains or mDC
subjected to various treatments were lysed and mRNA was extracted with an RNeasy kit
(Qiagen, Valencia, CA). Reverse transcription was done with SuperScript II (Invitrogen) and
the cDNA samples were analyzed by real-time quantitative PCR assay with an ABI Prism
7500 Sequence Detection system (Applied Biosystems). Reactions were incubated for 2 min at
50°C, denatured for 10 min at 95°C, and subjected to 40 two-step amplification cycles with
annealing-extension for 60°C for 1 min followed by denaturation at 95°C for 15s. For the
analysis of human TSLP, human TNFα, human GAPDH, human CXCR4, and human CCR5
real time PCR probes were purchased directly from the manufacturer (SuperArray). For the
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analysis of human TARC and MDC the primer sequences were as follows:

TARC: 5´-

CATGGCCCCACTGAAGATG-3´ and 5´-CCTGGAGCAGTCCTCAGATGTC-3´ and; MDC:
5´-GCATGGCTCGCCTACAGACT-3´ and 5´-CAGACGGTAACGGACGTAATCA-3´. For
the analysis of human IL-4, IL-5, IL-10, IL-13, TNF-α and INF-γ, the primer sequences were as
follows: IL-4: 5´-CACCGAGTTGACCGTAACAG-3´ and 5´-GCCCTGCAGAAGGTTTCC3´; IL-5: 5´-AGCTGCCTACGTGTATGCCA-3´ and 5´-GCAGTGCCAAGGTCTCTTTCA3´;

IL-10:

5´-GAGATCTCCGAGATGCCTTCA-3´

and

5´-

CAAGGACTCCTTTAACAACAAGTTGT-3´; IL-13: 5´-ACAGCCCTCAGGGAGCTCAT3´

and

5´-TCAGGTTGATGCTCCATACCAT-3´

and

INF-γ:

5´-

GTTTTGGGTTCTCTTGGCTGTTA-3´ and 5´-AAAAGAGTTCCATTATCCGCTACATC3´. Fold increase in the expression of various genes was calculated by normalizing to medium
control.
Ex vivo vaginal tissue explant model for HIV-induced TSLP expression: These studies
were done in collaboration with colleagues from the Fred Hutchinson’s Cancer Center (FHCC),
Seattle, WA where the tissues were collected and exposed to HIV for various times before
shipping the tissue and culture supernatant samples to Houston, TX. Study details at our
colleagues from Seattle include the following: Tissues were collected from patients in operating
room and placed into specimen containers holding cold RPMI or PBS and transported to lab on
ice within 1 hour [29] following institutional guidelines for collecting and handling the human
samples at FHCC, Seattle, WA. The tissues were then processed by removing the excess
stroma by gross dissection followed by washing in PBS to remove excess blood from surface.
Forceps were used to pull any residual clots off. Tissues were cut into strips (5mm x 10mm)
and placed in PBS. Tissues were washed 3 times with 50 ml PBS by filling 50 ml conical tube
with PBS and inverting tube several times. Tissue pieces were allowed to settle before pouring
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PBS off carefully.

PBS + 5mM EDTA was added to tissue strips. Tissues were incubated

over night at 4°C with shaking. The next day the epithelium was peeled carefully from the
stroma using a dissecting microscope. The sheets were washed in HBSS + 5mM CaCl2 and
incubated in Hank’s Buffered Saline Solution (HBSS) + 5mM CaCl2 for 30 min on ice. The
sheets were then placed in 6 well plates with the final volume/well equaling 3ml. The sheets
were spinoculated with virus (p24 Dosage ~0.05ug/ml), at 2300 RPM for 2 hours at 37°C. Post
spinoculation the sheets were extensively washed in PBS (~10 times). Fresh RPMI
supplemented with 10% fetal bovine serum (FBS) and the appropriate antibiotics was added
and the sheets were carefully placed in CO2 incubators at 37°C for up t0 4 days. For confocoal
microscopy virus-challenged epithelial sheets were incubated in PBS containing 1% bovine
serum albumin and 0.05% sodium azide for 1 hr at RT antibodies to CD1a (NA1/34; Dako,
Carpinteria, CA) or TSLP (MD Anderson core Facility). Sheets were washed in PBS
containing 1% bovine serum albumin and 0.05% sodium azide and incubated for 30 min with
the appropriate secondary antibodies, washed again, and fixed overnight in 4%
paraformaldehyde. Nuclei were counterstained with TOPRO3 (Molecular Probes), and the
sheets were embedded in Mowiol 40-88 containing 2.5% w/v DABCO (Aldrich,
Milwaukee, WI). Cellular staining was visualized with a Leica TCS SP spectral confocal
microscope.
HIV Infection Assay: Virus production in HIV-infected cells was analyzed by determining
the reverse transcriptase (RT) activity as reported earlier [98]. Viral particles from the infected
culture supernatants were precipitated with 30% polyethylene glycol (50% volume/volume)
and pelleted by centrifugation at 3000 rpm for 30 min at 4°C.

The viral pellets were

resuspended in 100 µl of RT buffer (glycerol, 25mM Tris-HCl, pH 7.5, 5mM dithiothreitol,
150mM KCl and 0.025% Triton X-100) followed by lysing with the addition of 100µl of 0.9%
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Triton X-100 in 1.5 M KCl. A 10µl aliquot of this preparation was mixed with 90µl of the RT
cocktail (50 mM Tris-HCl, pH 7.8, 63 mM KCl, 4.2mM MgCl2 , 0.08% Nonidet P-40, 0.85mM
EDTA, 4.2 µg/ml poly(A), and 0.13 µg/ml of oligo(dT). 8 µl of 0.5 M DTT and 10 µl of
[Methyl-3H] (ICN Pharmaceuticals Inc., Irvine, California, U.S.A.) and incubated at 37°C for
1.5 hr. The reaction mix was precipitated with 10% trichloroacetic acid (TCA) and 1% sodium
pyrophosphate. The TCA precipitable raw counts per minute (cpm) were determined on a
Wallace 1409 liquid beta-scentillation counter (Wallace, Gatthersburg, MD).

The mean

radioactivity for the duplicate infections was determined and the mean background cpm values
from duplicate samples of uninfected control cultures run in parallel in each assay were
subtracted to calculate the specific RT activity in the infected cell cultures.
ELISA. Concentrations of the TSLP, MDC or TARC protein in cell-free supernatants and cell
lysates were measured using respective specific ELISA kits (R&D Systems). The minimal
detection limit for TSLP is set to 31.25 pg/ml, MDC is set to 62.5 pg/ml, and TARC is set to 7
pg/ml.
Western Blot Analysis HIV-induced TSLP production: Aliquots of 2 x 107 epithelial cells
exposed to HIV were subjected to lysis in 2x Laemmli buffer. The lysates were then mixed
with 4x loading buffer (4mL glycerol, 0.4g SDS, 2.5 ml 1M Tris-HClL, pH 6.8, 80 μl
bromophenol blue, H2O to 8 ml, 20% βMe) and resolved on a 17.5% SDS polyacrylamide gel
followed by western blot analyses using rat anti-TSLP (mAb 12F3, DNAX, Palo Alto, CA) at a
dilution of 1:1000 as the primary antibody and horseradish peroxidase labeled donkey anti-rat
IgG H&L secondary antibody (diluted 1:10,000,) and the femto fluorometric system (Pierce
Biotechnology).
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Transfection and Luciferase Assay: Cervical epithelial cells (3 x 105) were transfected, using
the calcium phosphate method, with 1µg of luciferase reporter plasmid driven by the TSLP
promoter encoding either wild-type or mutated NFkB elementand 15ng of control renilla
luciferase reporter driven by a constitutive thymidine kinase promoter (pRL-tk-luc) (Promega).
The TSLP promoter plasmids were obtained from Dr. Steven F. Ziegler at the University Of
Washington School Of Medicine. The cells were cultured for 48 hours and then exposed to IL1 and HIV overnight. Cells were harvested and lysed in 100ul of lysis buffer. Luciferase
activity was measured using a Lumat LB9507 luminometer to determine whether HIV exposure
of epithelial cells resulted in an induction of luciferase expression as robust as that previously
seen with IL-1 . Relative Luciferase activity was calculated as a ratio of relative light units to
relative Renilla Luciferase units. In each experiment, samples were analyzed in triplicate and
each experiment was repeated at least three times.
Generation of C33A cells expressing an NF-kB super-repressor: An IkBa mutant harboring
mutations in its phosphorylation sites, serines 32 and 36 (named IkBaSS/AA,[99]), was cloned
into the retroviral vector pMIGR1 (provided by Warren Pear, Abramson Family Cancer
Research Institute). Since the IkBaSS/AA is resistant to inducible degradation (34), it functions
as a super-repressor of NF-kB. To produce recombinant retroviruses, pMIGR1-IkBaSS/AA or
pMIGR1 vector control was transiently transfected into 293 cells along with the packaging
plasmid pCL-Ampho and the VSV-G plasmid, as previously described [100]. The recombinant
viruses were used to infect C33A cells, which were used as bulk of cells in the experiments.
Analyses of surface gp340 expression:

Various epithelial cell lines employed in the

investigation were grown in 12 well plates and harvested with PBS containing 5mM EDTA.
Fluorescence staining of the cells was performed in the presence of 4mM Ca2+. Mouse antigp340 (abcam, Cambridge, MA) in PBS (1:100 dilution), 2% FBS, 4mM Ca2+ was added to the
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cells for 30 min on ice. Next, cells were incubated with a FITC labeled goat anti-mouse
secondary antibody (Abcam) (1:200 dilution) for 30 minutes at 4oC and protected from light.
The cells were then washed 3x with PBS and fixed with 1.0% paraformaldehyde. Stained and
fixed cells were analyzed by a FacsCalibur flow cytometer (BD Biosciences, San Diego, CA)
using Flowjo software (Ashland, OR).
Transfection of gp340 into gp340-null Fadu cells: Fadu cells were transfected with an
expression vector containing gp340 cDNA (OriGene) using the calcium phosphate method.
The expression of gp340 was confirmed by FACS analysis and RT-PCR. For the analysis of
human gp340 and TLR3 expression (as internal control gene expression), the primer sequences
used

were

as

follows:

TLR3:

5'-AGCCTTCAACGACTGATGCT-3',

and

5'-

TTTCCAGAGCCCTGCTAAGT-3', for gp340: 5'-AAATTCATCCTATGGTCTA-3', and 5'GAGAGGGGAACTCCGGTAG-3'.
Knock down of gp340 knock in gp340+ C33A cells: The C33A cervical epithelial cells were
seeded at 3 x 104 cells per well in 24-well culture plates and incubated for 2 days (to reach
about 40–60% confluence) before transfecting with siRNA against gp340 or non-target control
RNA at 5 nM (Dharmacon) using LipofectAmine 2000 transfection reagent (Invitorgen)
following the manufacturer’s instructions. Subsequently, the cells were cultured for another 48
h and the level of gp340 knockdown was confirmed by FACS analysis and RT-PCR.
Transmission Electron Microscopy for detection of HIV endocytosis: The C33A and Fadu
human epithelial cells were grown to 50-60% confluency in 12 well plates.

Cells were

incubated with HIV for 2 hrs at 4°C and then moved to 37°C for 30min. Samples were fixed
with a solution containing 3% glutaraldehyde plus 2% paraformaldhyde in 0.1M cacodylate
buffer, pH 7.3 for 1 hour. Further processing of the samples was performed by personnel in our
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institutional electron microscopy core facility as follows:, the samples were washed and treated
with 0.1% Millipore-filtered cacodylate buffered tannic acid, postfixed with 1% buffered
osmium tetroxide for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate.
The samples were dehydrated in increasing concentrations of ethanol, infiltrated, and
embedded in LX-112 medium. The samples were polymerized in a 70°C oven for 2 days.
Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with
urnanyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010
transmission electron microscope (JEOL, USA, Inc, Peabody, MA) at an accelerating voltage
of 80kV. Digital images were obtained using AMT Imaging System (Advanced Microscopy
Techniques Corp, Danvers, MA).
Knock down of TLR7 and TLR8 expression C33A cells: The C33A cervical epithelial cells
were seeded at 3 x 104 cells per well in 24-well culture plates and incubated for 2 days (to reach
about 40–60% confluence) before transfecting with siRNA against TLR7, TLR8 or non-target
control RNA at 5 nM (Invitrogen) using DOTAP liposomal transfection reagent (Roche
Diagnostics Corp) following the manufacturer’s instructions. Subsequently, the cells were
cultured for another 48 h and the level of TLR7 or TLR 8 knockdown were confirmed by FACS
analysis and RT-PCR.

For the analysis of human TSLP human TLR7 or human TLR8, RT-

PCR primers were purchased directly from the manufacturer (Invivogen).
Determination of the involvement of RXR in HIV induced TSLP Expression: Cervical
epithelial cells co-treat with 9-cis-RA in the presence of HIV, IL-1β, or polyI:C overnight and
analyzed for TSLP expression by both mRNA analysis. 9-cis-RA was a gift from Dr. Kapil
Mehta at UT MD Anderson Cancer Center (Houston, TX)
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Statistical analyses: Using the Student t-test the P values were calculated to determine the
significance of fold increase in CD4+T cells and HIV infection (RT activity).
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